


# Cell Stem Cell

## Single-Cell Transcriptomic Analysis of Cardiac Differentiation from Human PSCs Reveals HOPX-Dependent Cardiomyocyte Maturation

### Graphical Abstract



### Authors

Clayton E. Friedman, Quan Nguyen, Samuel W. Lukowski, ..., Patrick P.L. Tam, Joseph E. Powell, Nathan J. Palant

### Correspondence

j.powell@garvan.org.au (J.E.P.),  
n.palant@uq.edu.au (N.J.P.)

### In Brief

Friedman et al. performed single-cell transcriptional analysis over a time course of *in vitro* cardiac differentiation from human pluripotent stem cells. They utilized these data to identify the requirement of hypertrophic stimuli for expression of a cardiac regulatory gene, HOPX, to generate cardiomyocytes more accurately reflecting *in vivo* heart development.

### Highlights

- Single-cell RNA-seq during cardiac hPSC differentiation reveals cellular heterogeneity
- A key cardiac regulatory gene, HOPX, is rarely expressed during *in vitro* differentiation
- HOPX is a key *in vitro* regulator of cardiomyocyte hypertrophy and maturation



# Single-Cell Transcriptomic Analysis of Cardiac Differentiation from Human PSCs Reveals HOPX-Dependent Cardiomyocyte Maturation

Clayton E. Friedman,<sup>1,2,14</sup> Quan Nguyen,<sup>1,14</sup> Samuel W. Lukowski,<sup>1,14</sup> Abigail Helfer,<sup>1,2</sup> Han Sheng Chiu,<sup>1,2</sup> Jason Miklas,<sup>8</sup> Shiri Levy,<sup>8</sup> Shengbao Suo,<sup>4</sup> Jing-Dong Jackie Han,<sup>4</sup> Pierre Osteil,<sup>5</sup> Guangdun Peng,<sup>6</sup> Naihe Jing,<sup>6,7</sup> Greg J. Baillie,<sup>1</sup> Anne Senabouth,<sup>1</sup> Angelika N. Christ,<sup>1</sup> Timothy J. Bruxner,<sup>1</sup> Charles E. Murry,<sup>8</sup> Emily S. Wong,<sup>3</sup> Jun Ding,<sup>9</sup> Yuliang Wang,<sup>8,10</sup> James Hudson,<sup>13</sup> Hannele Ruohola-Baker,<sup>8</sup> Ziv Bar-Joseph,<sup>9</sup> Patrick P.L. Tam,<sup>5,11</sup> Joseph E. Powell,<sup>1,12,15,\*</sup> and Nathan J. Palpant<sup>1,2,3,15,16,\*</sup>

<sup>1</sup>Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia

<sup>2</sup>Centre for Cardiac and Vascular Biology, The University of Queensland, Brisbane, QLD 4072, Australia

<sup>3</sup>School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia

<sup>4</sup>Key Laboratory of Computational Biology, Chinese Academy of Sciences-Max Planck Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 200031, China

<sup>5</sup>Embryology Unit, Children's Medical Research Institute, The University of Sydney, Westmead, NSW 2145, Australia

<sup>6</sup>State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; University of Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 200031, China

<sup>7</sup>School of Life Science and Technology, ShanghaiTech University, 100 Haik Road, Shanghai 201210, China

<sup>8</sup>Departments of Pathology, Biochemistry, Bioengineering and Medicine/Cardiology, Institute for Stem Cell and Regenerative Medicine, The University of Washington, Seattle, WA 98195, USA

<sup>9</sup>Computational Biology Department, School of Computer Science, Carnegie Mellon University, Pittsburgh, PA 15213, USA

<sup>10</sup>Paul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, WA 98195, USA

<sup>11</sup>School of Medical Sciences, Sydney Medical School, University of Sydney, NSW 2006, Australia

<sup>12</sup>Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute for Medical Research, Sydney, NSW 2010, Australia

<sup>13</sup>Queensland Institute for Medical Research, Brisbane, QLD 4006, Australia

<sup>14</sup>These authors contributed equally

<sup>15</sup>Senior author

<sup>16</sup>Lead Contact

\*Correspondence: [j.powell@garvan.org.au](mailto:j.powell@garvan.org.au) (J.E.P.), [n.palpant@uq.edu.au](mailto:n.palpant@uq.edu.au) (N.J.P.)

<https://doi.org/10.1016/j.stem.2018.09.009>

## SUMMARY

Cardiac differentiation of human pluripotent stem cells (hPSCs) requires orchestration of dynamic gene regulatory networks during stepwise fate transitions but often generates immature cell types that do not fully recapitulate properties of their adult counterparts, suggesting incomplete activation of key transcriptional networks. We performed extensive single-cell transcriptomic analyses to map fate choices and gene expression programs during cardiac differentiation of hPSCs and identified strategies to improve *in vitro* cardiomyocyte differentiation. Utilizing genetic gain- and loss-of-function approaches, we found that hypertrophic signaling is not effectively activated during monolayer-based cardiac differentiation, thereby preventing expression of HOPX and its activation of downstream genes that govern late stages of cardiomyocyte maturation. This study therefore provides a key transcriptional roadmap of *in vitro* cardiac differentiation at single-cell resolution, revealing fundamental mechanisms underlying heart development and differentiation of hPSC-derived cardiomyocytes.

## INTRODUCTION

Studies of cardiac development at single-cell resolution have provided valuable insights into cell diversity and genetic regulation of cardiovascular differentiation and morphogenesis *in vivo* (DeLaughter et al., 2016; Li et al., 2016). Human pluripotent stem cells are a key model system to study human cardiovascular developmental biology (Murry and Keller, 2008). However, it is well understood that cardiac differentiation *in vitro* does not generate cardiomyocytes with the transcriptional profile, cellular diversity, morphometry, or functional maturity of adult *in-vivo*-derived cardiomyocytes (Yang et al., 2014). The fidelity by which cardiac-directed differentiation *in vitro* recapitulates the transcriptional programs governing diverse cell fates generated *in vivo* has not been well characterized.

In this study, we report RNA sequencing data captured from more than 40,000 single cells navigating stage-specific transitions through *in vitro* cardiac-directed differentiation from pluripotency using an established small-molecule Wnt modulation protocol (Burridge et al., 2014; Lian et al., 2012). In coordination with a companion paper (Nguyen et al., 2018), we utilize the power of this dataset to expand our understanding of stem cell-directed differentiation as a platform to study cardiovascular development. Since heart development *in vivo* requires instructive cues from exogenous sources like signaling

from endoderm and mechanical forces of heart beat and growth, we aimed to leverage single-cell transcriptomic data to identify critical signaling or mechanical strategies for differentiating hPSCs to more accurately understand the identity of and control derivation of cardiac fates. We identify the non-DNA binding homeodomain protein *HOPX*, a key regulator of heart development (Jain et al., 2015) and hypertrophy (Chen et al., 2002; Kook et al., 2003; Shin et al., 2002) as dysregulated during differentiation and a potential cause for the immature state of hPSC-derived cardiomyocytes *in vitro*. Taken together, these data provide a unique resource for the field and identify a previously unappreciated strategy for enhancing differentiation of hPSC-derived cardiomyocytes *in vitro* for applications in cardiovascular biology.

## RESULTS

### Single-Cell RNA Sequencing Analysis of Cardiac-Directed Differentiation

To gain insights into the genetic regulation of cardiovascular development, we performed single-cell transcriptional profiling of human induced pluripotent stem cells (iPSCs) navigating from pluripotency through stage-specific transitions in cardiac differentiation (Figure 1A). Small-molecule Wnt modulation was used as an efficient method to differentiate pluripotent cells toward the cardiac lineage (Burridge et al., 2014; Lian et al., 2012). WTC CRISPRi GCaMP human induced pluripotent stem cells (hiPSCs) (Mandegar et al., 2016) were chosen as the parental cell line for this study. These cells are genetically engineered with a doxycycline-inducible nuclease-dead Cas9 fused to a Krüppel associated box (KRAB) repression domain. The versatility of this line provides a means to use this single cell RNA (scRNA)-seq data as a reference point for future studies aiming to assess the transcriptional basis of cardiac differentiation at the single-cell level. We captured cells at time points corresponding to stage-specific transitions in cell state including pluripotency (day 0), germ layer specification (day 2), and progressing through progenitor (day 5), committed (day 15), and definitive (day 30) cardiac cell states. A total of 44,020 cells were captured of which 43,168 cells were retained after quality control analysis. In total, we captured expression of 17,718 genes. Dimensionality reduction approaches were used to visualize all 43,168 cells in low-dimensional space (Figure 1B), in which each cell's coordinates were estimated so that they preserve the expression similarity in *t*-SNE plots (left), and differentiation pseudotime in diffusion plots (right).


We generated a time-course gene expression profile using a wide range of known cardiac developmental genes by measuring expression among all cells to reveal the temporally restricted expression dynamics of stage-specific genes reflecting cardiac fate choices (Figure 1C). To confirm that the differentiation follows known developmental trajectories, we used dimensionality reduction methods (Coifman et al., 2005; Moignard et al., 2015) (Figure 1D) and unsupervised clustering (Clustering at Optimal REsolution [CORE] [Nguyen et al., 2018]) (Figure 1E) to analyze the expression of known genes. Overall, these data show that small-molecule-mediated cardiac-directed differentiation generates distinct populations of

cells displaying expected temporal-specific transcriptional profiles. Our parallel computational genomics study (Nguyen et al., 2018) presents a web interface (<http://computationalgenomics.com.au/shiny/hipsc2cm/>), provided as complementary resources for this study.

### Phenotypic Diversity and Lineage Heterogeneity during Differentiation

With recent developments in high-resolution transcriptomic mapping of mouse *in vivo* development of the cardiovascular system (DeLaughter et al., 2016; Li et al., 2016), we set out to map single-cell heterogeneity of human *in-vitro*-derived subpopulations against *in vivo* cell subpopulations. Using previously published approaches, laser microdissection was used to capture spatiotemporal transcriptional data from germ layer cells of mid-gastrula stage (E7.0) embryos (Peng et al., 2016), with an expanded analysis to include early- (E6.5) and late-gastrulation (E7.5) mouse embryos (unpublished data) (Figure S1). To determine phenotypic identities based on gene expression networks governing each human *in-vitro*-derived subpopulation during differentiation, we visualized the spatiotemporal patterns of gene expression in the gastrulating mouse embryo including: *EOMES* (pan-mesendoderm), *MESP1* and *MIXL1* (mesoderm), *SOX17* and *FOXA2* (endoderm), and *NKX2-5* (cardiac lineage transcription factor) (Figures 2A and S2).

We subsequently dissected the transcriptional phenotype of subpopulations identified during human cardiac-directed differentiation. From pluripotency (Figures S3A and S3B), cells navigate through germ layer specification (day 2), comprising three transcriptionally distinct subpopulations expressing the pan-mesendoderm gene, *EOMES* (Figures 2B, 2C, and S2A) with subpopulations expressing genes involved in mesoderm (D2:S2), mesendoderm (D2:S3), and definitive endoderm (D2:S1) (Figures 2B, 2C, S2D, S3C, and S3D). Gene ontology (GO) analysis of differentially expressed genes between subpopulations indicated that only D2:S2 (34% of cells at day 2) showed significant enrichment for cardiogenic gene networks (Figure 2D; Table S1). At the progenitor stage (day 5), we identified cardiac precursors (D5:S1 and D5:S3) (Figures 2E, 2G, and S3E), a persistent population of definitive endoderm (D5:S2) (Figures 2E, 2F, and S3E), and a small population of endothelial cells in D5:S3 (Figures 2E–2G). Day 15 and day 30 cells comprised two subpopulations (Figures 2H–2M, S3F, and S3G). *NKX2-5*, *MYH6*, *TTN*, and other cardiac structural and regulatory genes were identified in S2 (Figures 2H–2M, S3F, and S3G). In contrast, S1 was primarily characterized by GO enrichment for genes associated with extracellular matrix deposition, motility, and cell adhesion (Figures 2J and 2M), which was supported by identification of a significant number of fibroblast-like cells marked by *THY1* (*CD90*) (Figures 2I and 2L). The co-existence of a non-contractile cell population, which is characterized as non-myocytes, is common in directed cardiac differentiation (Dubois et al., 2011). Taken together, these data show iPSC differentiation into committed (day 15) and definitive (day 30) cardiomyocytes (S2) and non-contractile cells (S1) (Figure 2N). To assess the level of maturity derived from this protocol relative to *in vivo* human development, we compared day 30 clusters against ENCODE RNA-sequencing (RNA-seq) data from fetal and adult hearts



**Figure 1. Single-Cell Analysis of Cardiac-Directed Differentiation**

(A) Schematic of protocol for small-molecule-directed differentiation from pluripotency into the cardiac lineage. hPSC, human pluripotent stem cell; GLS, germ layer specification; PC, progenitor cell; cCD, committed cardiac derivative; dCD, definitive cardiac derivative.

(B) Single cell ( $n = 43,168$  in total) analysis of cardiac differentiation beginning at pluripotency (day 0) and transitioning through mesoderm (day 2) into progenitor (day 5), committed (day 15), and definitive (day 30) cardiac derivatives. Data are presented using t-SNE plot, pseudospacing cells by the nonlinear transformation of similarity to preserve the local and global distance of cells in multidimensional space when embedded into two dimensional t-SNE space (left), and diffusion plot, pseudospacing cells in a trajectory based on diffusion distance (transition probability) between two cells (right).

(C) Mean gene expression across all cells at individual time points showing proper temporal expression of stage-specific genes governing differentiation into the cardiac lineage. Shown are pluripotency genes (*DNMT3B*, *POU5F1*, *NANOG*), mesoderm genes (*EOMES*, *MIXL1*, *T*, *MESP1*), and genes governing cardiomyocyte differentiation including signaling regulators (*TMEM88*), transcription factors (*ISL1*, *HAND1*, *NKX2-5*, *TBX5*, *GATA4*), calcium handling genes (*ATP2A2*, *PLN*), and sarcomere genes (*TNNI1*, *MYH6*, *MYH7*, *MYL7*). Data are represented as mean  $\pm$  SEM.

(D) Diffusion plots showing pseudospacing at single-cell resolution for gene expression of stage-specific genes during differentiation based on known genetic regulators of cardiac fate specification including *POU5F1* (day 0), *EOMES* (day 2), *TMEM88* (day 5), *TNNI1* (day 15), and *TTN* (day 30). Cells are colored in a binary manner. If the cell expresses the gene, it is colored according to the day of isolation (0, 2, 5, 15, or 30). Non-expressing cells are shaded gray.


(E) Representation of unsupervised clustering analysis (Nguyen et al., 2018) using t-SNE plots to show single-cell level expression of stage-specific gene expression at each day of differentiation based on known genetic regulators of cardiac fate specification including *POU5F1*, *EOMES*, *ISL1*, *TNNI1*, and *MYL7*. If the cell expresses the gene, it is colored according to subpopulation 1–4 in which the cell is associated. Non-expressing cells are shaded gray. Above each t-SNE plot, the percentage of cells expressing the gene in each subpopulation is shown together with the expression density plot and the reference t-SNE plot. UMI, unique molecular identifier.

(Figure 2O). Using genes that reflect either early fetal (*TNNI1*, *MYH6*) versus late stages of heart development (*MYH7*, *TNNI3*, *MYL2*), the most differentiated *in-vitro*-derived cardiac population (D30:S2) remains more developmentally immature than even first trimester human hearts.

## Lineage Predictions Based on Regulatory Gene Networks Governing Differentiation

We next sought to understand the lineage trajectories and gene regulatory networks governing diversification of cell fates. We implemented a probabilistic method for constructing regulatory





**Figure 2. Subpopulation Identification and Characterization**

(A) Corn plots showing spatial domains of *EOMES*, *MESP1*, *SOX17*, and *NKX2-5* expression in the mesoderm and endoderm of E6.5, E7.0, and E7.5 mouse embryos during gastrulation (unpublished RNA-seq data for E6.5 and E7.5 mouse embryos and published data for E7.0 mouse embryos [Peng et al., 2016]). Positions of the cell populations (“kernels”) in the 2D plot of RNA-seq data in the germ layers: the proximal-distal location in descending numerical order (1 = most distal site) and in the transverse plane of the mesoderm and endoderm—anterior half (EA) and posterior half (EP) of the endoderm, anterior half (MA) and posterior half (MP) of the mesoderm, posterior epiblast (P) containing the primitive streak, and expression from anterior (A) to posterior (P) primitive streak (only for *EOMES*).

(legend continued on next page)

networks from single-cell time series expression data (*scdiff*: cell differentiation analysis using time-series single-cell RNA-seq data) (Ding et al., 2018). The algorithm utilizes transcription factor (TF)-gene databases to model gene regulation relationships based on the directional changes in expression of TFs and target genes at parental and descendant states.

The algorithm identified three distinct lineages from pluripotency comprising 10 nodes (Table S2; Figure 3A). Since this algorithm reassigns cells based on regulatory networks, we analyzed the distribution of cell subpopulations based on our CORE cluster classifications as outlined in Figure 2 to establish population identities linking predicted lineages (Figures 3A, 3B, and S4A). The first lineage (N1:N2) diverts from pluripotency into a *SOX17/FOXA2/EPCAM*<sup>+</sup> definitive endoderm population that terminates at day 2 and comprises almost exclusively D2:S1 and D2:S3 (Figures 3A, 3B, and S4A). The second lineage, N1:N3:N5, transitions from pluripotency (N1) into node 3 comprising definitive endoderm (D2:S1) and mesendoderm (D2:S3) and is predicted to terminate at day 5 node 5 comprising *FOXA2/EPCAM*<sup>+</sup> definitive endoderm cells (D5:S2 and D5:S4) (Figures 3A, 3B, and S4A). The third lineage comprises the longest trajectory through differentiation involving transitions in cardiac fate (N1:N4:N6–N9 and N6–N10). Pluripotent cells (N1) give rise on day 2 to node 4 mesoderm (D2:S2) and mesendoderm (D2:S3) cells with subsequent progression on day 5 into cardiac precursor cells (N6: primarily D5:S1 and D5:S3). From day 5 the algorithm predicts a bifurcation of fate giving rise to *THY1*<sup>+</sup>/*NKX2-5*<sup>+</sup> non-contractile cardiac derivatives (N8–N10: D15:S1 and D30:S1) or *NKX2-5*<sup>+</sup>/*MYH6*<sup>+</sup> committed CM (N7: D15:S2) that progress onto *MYH7*<sup>+</sup>/*MYL2*<sup>+</sup> definitive CM (N9: D30:S2) (Figures 3A, 3B, and S4A).

We leveraged the regulatory network predictions to identify key transcription factors and target genes underlying progressive fate changes across all 10 nodes (Figure 3C; Table S2).

These data reinforce established mechanisms of cardiac lineage specification. In particular, we found evidence for downregulation of Wnt/ $\beta$ -catenin signaling (LEF1) between N4 and N6, which is required to transition from mesoderm into the cardiac progenitor cell (Palpant et al., 2013; Ueno et al., 2007). From the progenitor node N6 into contractile cardiomyocytes N7:N9, the data show proper downregulation of progenitor transcription factors such as *YY1* and upregulation of TFs known to control cardiomyocyte differentiation such as *NKX2-5* (Figure 3C).

We next sought to understand gene networks underlying specification of non-contractile cardiac derivatives N8:N10, a population currently not well defined although widely used for tissue engineering applications (Thavandiran et al., 2013). The predicted network underlying this transition showed significant downregulation of cardiac TFs *NKX2-5* and *MAZ* and upregulation of Pre-B cell leukemia transcription homeobox (*PBX1*:  $p = 1.1 \times 10^{-16}$ , mean DE target fold change = 2.72), a transcriptional regulator that activates a network of genes associated with cardiac outflow tract (OFT) morphogenesis (Arrington et al., 2012) (Figure 3C).

We compared expression of a panel of cardiomyocyte, early developmental vascular endothelial, and OFT development genes across all subpopulations comprising transitions from day 5 to 30 (Figure 3D). While early developmental vascular EC differentiation genes (*TAL1*, *CDH5*) were expressed in D5:S3, these genes were not expressed in D15 or D30. Furthermore, while D15 and D30:S2 cells expressed cardiac sarcomere genes and transcription factors (*IRX4* and *HCN4*), S1 cells uniquely expressed an extensive network of genes associated with OFT development including *PITX2*, *TBX18*, *HOXA1-3*, *FGF10*, *GJA1*, and *KDR* (Figure 3D). To determine the strength of this association, we performed GO analysis of differentially expressed genes between D30:S1 (N10) and D30:S2 (N9) cells. These data show a significant enrichment for gene networks related

(C, F, I, and L) Below each gene name are shown the following data from left to right: *t*-SNE plot and diffusion plot of cells expressing each gene, percentage of cells expressing gene, expression level of gene in each subpopulation.

(B–D) Analysis of day 2 subpopulations represented by (B) reference *t*-SNE (left) and diffusion (right) plots and the percentage of cells in each subpopulation (D2:S1–S3), (C) analysis of primitive streak genes *EOMES* (pan-mesendoderm transcription factor), *MESP1* (cardiogenic mesoderm transcription factor), and *SOX17* (definitive endoderm transcription factor).

(D) Gene ontology analysis of differentially expressed genes showing enrichment for networks governing cardiac development enriched in subpopulation 2.

(E–G) Analysis of day 5 progenitor subpopulations represented by (E) reference *t*-SNE (left) and diffusion (right) plots and the percentage of cells in each subpopulations (D5:S1–S4), (F) analysis of progenitor genes *TAL1* (endothelial fate transcription factor), *TNNI1* (early development sarcomere isoform of *TNNI*), and *SOX17* (definitive endoderm transcription factor).

(G) Gene ontology analysis of differentially expressed genes showing enrichment for networks governing cardiac development (D5:S1), definitive endoderm (D5:S2), and endothelium (D5:S3).

(H–J) Analysis of day 15 subpopulations represented by (H) reference *t*-SNE (left) and diffusion (right) plots and the percentage of cells in each subpopulation (D15:S1–S2), (I) analysis of cardiac genes *MYL7* (early development sarcomere isoform of *MYL*), *NKX2-5* (cardiac transcription factor), and *THY1* (fibroblast marker).

(J) Gene ontology analysis of differentially expressed genes showing enrichment for networks governing extracellular matrix and cell motility (D15:S1) and cardiac development (D15:S2).


(K–M) Analysis of day 30 subpopulations represented by (K) reference *t*-SNE (left) and diffusion (right) plots and the percentage of cells in each subpopulations (D30:S1–S2), (L) analysis of cardiac genes *TNNI1* (early development sarcomere isoform of *TNNI*), *MYH7* (mature sarcomere isoform of *MYH*), and *THY1* (fibroblast marker).

(M) Gene ontology analysis of differentially expressed genes showing enrichment for networks governing system development and morphogenesis (D30:S1) and cardiac development (D30:S2).

(N) Overall phenotypic determinations of subpopulation identity based on *in vivo* anchoring genes outlined through stage-specific transitions in differentiation. CM, cardiomyocyte.

(O) Expression of cardiac genes in day 30 hPSC-derived cardiomyocytes relative to expression levels in human fetal and adult heart samples (ENCODE). Gene expression is measured as counts per million mapped reads, and each gene is internally normalized to maximum expression. UMI, unique molecular identifier.

(C, F, I, and L) Data are represented as mean  $\pm$  SEM. See also Figures S1–S3 and Table S1.



**Figure 3. Transcription Factor Regulatory Networks Predict Developmental Fate Choices During Cardiac Differentiation**

(A) Stepwise transitions into cardiac lineages from pluripotency predicted on the basis of gene regulatory networks (GRN) detected between pairwise changes in cell state during differentiation. Circles indicate distinct nodes governed by a common GRN. Since cells can be re-assigned based on the expression of their genes, the re-distribution of subpopulations established by clustering analysis and phenotyping as outlined in Figure 2 are represented as pie charts within each circle indicating the percentage of cells from each subpopulation contributing to that node. Each node is numbered N1–N10 for reference.

(B) Phenotypic identity of nodes reflecting stage-specific transitions in cell state through cardiac-directed differentiation.

(C) Analysis of transcription factors (TFs) and genes controlling stage-specific regulatory networks underlying cell fate transitions. Mean DE target fold change calculates the fold change for the differentially expressed targets of the TF. DE gene fold change shows up or downregulated fold change of TF target genes.

(D) Heatmap comparing expression across all cells from day 5, 15, and 30 subpopulations for genes involved in progenitor specification, vascular endothelial development, outflow tract development, and primary heart field cardiomyocyte development.

(E) Gene ontology analysis comparing day 30 S1 versus S2 showing gene networks involved in vascular development enriched in S1 versus cardiac muscle development enriched in S2.

(F) *t*-SNE and diffusion plots for all cells from days 15 and 30 showing expression distribution of the cardiac gene *MYH7* (high in S2 at day 15 and 30) relative to outflow tract development genes *THY1*, *PITX2*, and *BMP4* (high in S1 at day 15 and 30).

(G) The top most differentially expressed genes identified by *in vivo* single-cell analysis comparing outflow tract (OFT) versus ventricular cardiomyocytes (Li et al., 2016) compared against their expression level in D30:S1 versus D30:S2 *in-vitro*-derived cardiac derivatives.

(H) Differentially expressed genes between subpopulations D30:S1 and D30:S2 used to assess transcriptional similarity to *in vivo* cell types (Li et al., 2016; Quaife-Ryan et al., 2017) using Spearman's correlation analysis.

See also Figure S4 and Table S2.

to vascular development ( $p = 1.1 \times 10^{-11}$ ) and blood vessel morphogenesis ( $p = 4.7 \times 10^{-9}$ ) exclusively within node 10 D30:S1 cells. This finding is supported by single-cell visualization showing enrichment of OFT-associated genes expressed in S1 versus S2 including *THY1* (59% D30:S1 versus 2% D30:S2), *BMP4* (70% D30:S1 versus 6% D30:S2), and *PITX2* (73% D30:S1 versus 17% D30:S2) (Figures 3E and 3F).

To link this observation to *in vivo* cell types, we used single-cell RNA-seq data of *in vivo* heart development (Li et al., 2016) to identify the top most differentially expressed genes between OFT and left ventricle (LV). These data show expression of *BMP4*, *RSPO3*, *TNC*, and *COL1A2* in D30:S1 and *in vivo* OFT derivatives and *MYL2* and *HOPX* upregulated in cardiomyocytes

and expression of these genes similarly differentially expressed in D30 S1 versus S2 subpopulations (Figure 3G). To assess cell-type-specific transcriptional signatures, we identified differentially expressed genes between D30 S1 versus S2 and performed a Spearman rank correlation analysis against expression profiles of *in vivo* fluorescence-activated cell sorted (FACS) (Quaife-Ryan et al., 2017) or single-cell-derived cardiac subtypes (Li et al., 2016). These data show that D30:S1 has a significantly stronger correlation to OFT cells (Spearman's  $\rho = 0.442$ ) than to fibroblasts (Spearman's  $\rho = 0.219$ ), endothelium (Spearman's  $\rho = 0.175$ ), or myocardium (Spearman's  $\rho = 0.243$ ) ( $p < 2.2 \times 10^{-16}$  for all pairwise comparisons) (Figure 3H). Collectively, these data indicate that directed differentiation generates

definitive cell populations comprising contractile cardiomyocytes and a non-contractile cell type whose transcriptional signature correlates with cardiac OFT cells. Due to the complex cellular origins of cardiac OFT and the diversity of non-contractile cell types of the heart *in vivo*, further studies are required to determine the specific identity and biology of these cells and their application in disease modeling and tissue engineering.

### **HOPX Is Dysregulated during *In-Vitro*-Directed Differentiation from hPSCs**

We next aimed to identify dysregulated gene networks with the objective of determining different mechanisms for modeling *in vitro* differentiation to more accurately reflect *in vivo* heart development. Focusing on core regulatory genes governing transcriptional networks in heart development, we analyzed 52 transcription factors and epigenetic regulators known to govern diversification of mesoderm and endoderm lineages (Table S3). *HOPX*, a non-DNA binding homeodomain protein identified in this analysis, has previously been shown to be one of the earliest, specific markers of cardiomyocyte development (Jain et al., 2015) and governs cardiac fate by regulating cardiac gene networks through interactions with transcription factors, epigenetic regulators, and signaling molecules (Chen et al., 2002; Jain et al., 2015). We have also recently shown that *HOPX* functionally regulates blood formation from hemogenic endothelium (Palpant et al., 2017b). Consistent with mouse heart development, analysis of human fetal development at each trimester indicate a robust activation of *HOPX* during heart development *in vivo* (Figure S5A).

Previous studies have shown *HOPX* is expressed during cardiomyocyte specification at the progenitor stage of mouse development *in vivo* (Jain et al., 2015), whereas we detected *HOPX* only in endothelium (D5:C3) and not in cardiac precursor cells (D5:C1) at an equivalent time point (day 5) of *in vitro* differentiation (Figures 4A and 4B). Second, in contrast to previous studies *in vivo* where *HOPX* lineage traces almost all cardiomyocytes of the heart (Jain et al., 2015), *HOPX* is detected in only 16% of D30:S2 cardiomyocytes (Figures 4B–4D). To rule out stochastic expression in cardiomyocytes due to low sequencing read depth resulting in dropout, we analyzed expression of genes known to regulate cardiac lineage specification and differentiation (Figures 4C and 4D). While *HOPX* is rarely detected, its expression level is equivalent to that of other cardiac TFs that are detected in a high percentage of D30:S2 cardiomyocytes (*HAND1*: 67%, *HAND2*: 64%, *GATA4*: 67%, *NKX2-5*: 86% versus *HOPX*: 16%) (Figures 4B–4D).

We utilized expression data derived from *in vivo* development to evaluate *HOPX* expression during cardiovascular development. Assessment of gene expression during mouse gastrulation *in vivo* shows *HOPX* expression as early as E6.5 in the proximal portion of the nascent primitive streak (P) (Figures 4E, S5B, and S5C) similar to the expression pattern of *MESP1* (Figures S5D and S5E). From E7.0 to E7.5, *HOPX* is increasingly expressed throughout the developing endoderm. By E7.5, *HOPX* displays residual expression in the remaining distal primitive streak, endoderm (EA to EP), and the anterior mesoderm (MA) in coordination with other cardiogenic genes including *NKX2-5* and *MESP1* (Figures 4E and 2A). We analyzed *HOPX* expression across diverse cell types contributing to heart development

*in vivo* using single-cell transcriptomic analysis of the E9.5 mouse heart (Li et al., 2016). These data indicate that *HOPX* expression is distributed throughout all chambers and cell types of the heart. While *HOPX* expression largely coincides with expression of cardiac genes *MYH7* and *ACTN2*, *HOPX* is also expressed in endothelial cells (*CDH5*<sup>+</sup> and/or *PECAM1*<sup>+</sup>), smooth muscle cells (*MYH11*<sup>+</sup> and/or *TAGLN2*<sup>+</sup>), and epicardial cells (*WT1*<sup>+</sup>) (Figure 4F; Table S4).


### **Lineage Trajectory of *HOPX*-Expressing Cells *In Vitro***

We analyzed the lineage trajectory of *HOPX*<sup>+</sup> cells at single-cell resolution during cardiac-directed differentiation to determine the core gene networks and transcription factors governing successive fate choices of *HOPX*-expressing cells during cardiac differentiation (Figures S4B–S4D; Table S2). At day 2, rare *HOPX*-expressing cells are identified in mesendoderm (D2:S2 9% and D2:S3 6%) and rarely in definitive endoderm (D2:S1 2%) with the *HOPX* lineage comprising 2 lineages (N2 and N3) enriched for expression of cardiogenic mesoderm genes such as *MESP1* (Figures S3C and S3D). From day 2 into day 5, *HOPX*<sup>+</sup> cells remain sparse in progenitor cell populations where day 2 N3 splits into two day 5 lineages N4 and N5 (Figure S4B). Based on lineage prediction, an equal proportion of *HOPX*<sup>+</sup> cells give rise to *TNNI1*<sup>+</sup> cardiac precursor cells (N4: 389 cells) or *TAL1*<sup>+</sup>-expressing endothelial cells (N5: 381 cells) with both fates governed by established TFs and downstream gene networks required for endothelial (*NRP2*, *KDR*) versus cardiac fate specification (*TNNI1*, *TMEM88*) (Figures S4C and S4D; Table S2). Progressing to day 15 of differentiation, *HOPX* expression remains rare (2%–4% of cells) and splits into two separate lineages derived from day 5 cardiac precursor cells (N4). Governed in part by increased *NKX2-5* and downregulation of the cardiac progenitor TF *YY1*, *HOPX* cardiac cells differentiate into *MYL2/IRX4*<sup>+</sup> cardiomyocytes (N6–N7), while a separate branch governed by TFs such as *PBX1* differentiate into non-contractile derivatives (N8–N9) (Figures S4B–S4D).

### **Chromatin and Expression Analysis of *HOPX* in Cardiac Lineage Specification**

To determine the epigenetic basis for *HOPX* dysregulation during *in vitro* differentiation, we analyzed chromatin and transcriptional regulation at the *HOPX* locus (Palpant et al., 2017a) (Figure S5F). Chromatin immunoprecipitation data for repressive chromatin (H3K27me3), actively transcribed chromatin (H3K4me3), and gene expression by RNA-seq (Palpant et al., 2017b) show that in the context of cardiac-directed differentiation *HOPX* is epigenetically repressed on the basis of abundant H3K27me3 compared to H3K4me3 in day 5 cardiac precursor cells (Figure S5F). This is consistent with RNA-seq, quantitative real-time PCR, and analysis of *HOPX* activity in tdTomato knockin *HOPX* reporter cells showing that *HOPX* is expressed late during cardiac differentiation, well after sarcomere formation and weeks after the onset of spontaneously beating cells during cardiac-directed differentiation (Figures 4B, S5F, and S6A–S6D). The highest level of *HOPX* expression was observed in cardiomyocyte cultures maintained for 1 year (Figures S5F and S5G). Collectively, these data show a direct link between chromatin regulation of the *HOPX* locus and expression of *HOPX* in cardiac lineage specification *in vitro*.





**Figure 4. HOPX Is Rarely Expressed During *In Vitro* Cardiac-Directed Differentiation**

(A) Analysis of *HOPX* expression in eleven subpopulations from day 2 to day 30 of differentiation showing expression as early as day 2 mesoderm and highest expression in day 5 endothelial cells (ECs) and day 30 cardiomyocytes (CMs).

(B) Single-cell expression analysis of *HOPX* at day 2, 5, 15, and 30. Data presented include *t*-SNE plots indicating distribution and localization of *HOPX*-expressing cells in different subpopulations (bottom), the percentage of *HOPX*<sup>+</sup> cells in each subpopulation (top left), bar graphs showing expression of *HOPX* in each subpopulation (top middle), and the reference *t*-SNE plot demarcating subpopulations (top right). Data are represented as mean  $\pm$  SEM.

(C) Analysis of known genetic regulators of heart development only in subpopulation 2 at day 30 of differentiation.

(D) *t*-SNE plots of merged datasets from two continuous days for all cells between days 15 and 30 for each gene showing robust distribution of key cardiac regulatory genes with the exception of *HOPX*.

(E) Corn plots showing the spatial domains of *HOPX* expression in the mesoderm and endoderm of E7.0 and E7.5 mouse embryos during gastrulation (unpublished RNA-seq data for E7.5 embryos and published data for E7.0 embryo [Peng et al., 2016]) (Figure S1).


(F) Single-cell expression analysis of E9.5 mouse heart cells (Li et al., 2016) showing *Hopx* expression relative to markers of cardiomyocytes (*Myh7*, *Actn2*) and endothelial cells (*Cdh5*, *Pecam1*) (scale bars are Log<sub>2</sub>(CPM)). Table (right) shows percentage of cardiac (*Myh7*), endothelial (*Pecam1*), and smooth muscle (*Tagln2*) cells co-expressing *Hopx* in various regions of the developing mouse heart.

UMI, unique molecular identifier. (A and C) Data are represented as mean  $\pm$  SEM. See also Figures S4 and S5 and Table S4.

### HOPX Drives Cardiomyocyte Hypertrophy

To determine the functional role of *HOPX*, we established conditional *HOPX* overexpression hPSCs in which a nuclear localized *HOPX* is targeted to the AAVS1 locus (Figure 5A). Using western blot, quantitative real-time PCR, and immunostaining, we show that *HOPX* transcript and HOPX protein is overexpressed in a doxycycline-inducible manner and is nuclear localized (Figures 5A–5C). Morphometric analysis of dox-treated cardiomyocytes showed a significant increase in cell area under conditions of

*HOPX* overexpression (Figure 5D) consistent with previous studies showing that forced *Hopx* expression *in vivo* causes cardiac hypertrophy (Chen et al., 2002; Kook et al., 2003; Shin et al., 2002). We performed bulk RNA sequencing analysis on control versus *HOPX* OE cardiomyocytes to determine global transcriptional changes (Figures 5E–5H; Table S5). Analysis of differentially expressed genes showed a significant enrichment of gene ontologies associated with signaling pathways (*ERK1-2*, *IGF-1*) and gene networks involved in cell growth and maturation



**Figure 5. HOPX Is a Key Regulator of Cardiomyocyte Hypertrophy**

(A) Gene targeting strategy for conditional *HOPX* overexpression. Schematic shows design of conditionally expressed *HOPX*-NLS-eGFP construct. Below, western blot showing doxycycline induction of control (NLS-eGFP) and *HOPX* OE iPSC lines.

(B) qPCR analysis of *HOPX* transcript abundance in control versus *HOPX* OE iPSCs.

(C) Immunohistochemistry showing nuclear localization of *HOPX*-GFP in cardiomyocytes.

(D) Cell-size analysis showed that *HOPX* OE treated hiPSC-CMs led to a significant increase in area. Data are represented as mean ± SEM.

(E–G) Volcano plot (E), quantification of differentially expressed (DE) genes (F), and gene ontology analysis (G) of significantly differentially expressed genes ( $-1 < \log_2 FC < 1$ ;  $p_{adj} > 0.05$ ) identified by RNA-seq of control versus *HOPX* OE cardiomyocytes.

(H) Genes known to govern hypertrophy showing *IGF1* as the most significantly upregulated hypertrophic gene in *HOPX* OE versus control cells. For heatmaps, data are presented as Log<sub>10</sub>-transformed relative gene expression normalized to *HPRT*.

NLS, nuclear localization signal; eGFP, enhanced GFP. Scale bars, 100 μm. \* $p < 0.05$  by t test. See also Table S5.

in *HOPX* OE cardiomyocytes with *IGF-1* representing the most highly upregulated among a panel of known regulators of hypertrophy (Figures 5G and 5H and Table S5).


### The *HOPX* Locus Is Activated by Hypertrophic Stimulation

Hypertrophic stimulation is modeled poorly in high-density monolayer cardiac-directed differentiation due to the absence of exogenous hypertrophic signals. On the basis that this discrepancy may, at least in part, explain the dysregulation of *HOPX* *in vitro*, we tested the reciprocal hypothesis that exogenous hypertrophic stimuli is sufficient to drive *HOPX* expression *in vitro*. We implemented an established approach for stimulating hypertrophy (Uesugi et al., 2014) in which high-density monolayer-derived cardiomyocytes are replated at low density at day 10 and analyzed at day 15 (Figure 6A). In keeping with a hypertrophic response, replating cardiomyocytes results in significantly increased cell area, anisotropy (Figures 6B and 6C), and upregulation of genes governing cardiac hypertrophic growth including *NPPB*, *MYOCD*, *EDN1*, and *IGF-1* (Figure 6D). Importantly, we found that replating cardiomyocytes resulted in a greater than 10-fold increase in *HOPX* expression (Figure 6E) in coordination with significant increases in expression of myofibrillar isoforms (*MYH7*, *MYL2*, *TNNI3*) and transcription factors (*SRF*) involved in cardiomyocyte maturation (Figure 6F). To assess *HOPX* expression at single-cell resolution, we utilized

robustly activated uniformly in replated cardiomyocytes (Figure 6G). We further show that treatment with Endothelin-1 (ET-1), a potent stimulus of cardiomyocyte hypertrophy, significantly increases *HOPX* expression albeit to a much lower level than replated cardiomyocytes (Figure 6H). Taken together, these results indicate that transcriptional activation of the *HOPX* locus is downstream of hypertrophic signaling.

### Dissecting the Transcriptional Complexity of *HOPX* Regulation Underlying Cardiomyocyte Hypertrophy

While genetic loss of *HOPX* did not impact specification of cardiomyocytes (Figures S6E and S6F), we set out to study the functional requirement and underlying complexity of the *HOPX* locus in cardiomyocyte hypertrophy. To this end, we utilized CRISPRi loss-of-function hPSCs to conditionally block *HOPX* expression at each of its two transcriptional start sites, which we term the proximal transcriptional start site (TSS) (g4) and distal TSS (g1) (Figure 6I). Multiple exon-spanning primers were designed to map transcriptional activity across the *HOPX* locus (Figure 6I). Cells were differentiated into the cardiac lineage ± dox and analyzed at day 15 of differentiation under standard high-density monolayer conditions versus replating. All *HOPX* transcripts were significantly increased during replating (Figure 6J; Table S6). However, inhibition of the proximal TSS (g4) repressed expression from that locus (*HOPX* C) with no effect on transcriptional activity from the distal TSS (*HOPX* A) (Figure 6J). In



**Figure 6. *HOPX* Functionally Governs Cardiac Hypertrophy Through the Distal Transcriptional Start Site**

(A) Schematic of *in-vitro*-directed differentiation of hPSCs with re-plating at day 10 and analysis at day 15.

(B and C) Representative images (B) and quantification (C) of morphometric changes during replating including cell area and circularity.

(D) qPCR analysis of a selected panel of hypertrophic genes differentially expressed in the context of replating cardiomyocytes. HD, high-density monolayer.

(E and F) qPCR analysis showing significant increases in *HOPX* ( $n = 5-8$  biological replicates per condition from 3-4 experiments) (E) among a range of other cardiac transcription factors and myofibrillar genes ( $n = 6-8$  biological replicates per condition from 3 experiments) (F) involved in cardiomyocyte maturation in replated cardiomyocytes compared to controls.

(G) Immunohistochemistry of *HOPX*-tdTomato reporter cells showing uniform expression of *HOPX* in  $\alpha$ -actinin<sup>+</sup> replated cardiomyocytes.

(H) Treatment with the hypertrophic signaling molecule endothelin-1 (ET1) significantly increases *HOPX* expression.

(I) UCSC genome browser analysis of transcript variants mapped to the *HOPX* locus, the position of guide RNAs blocking the proximal (g1) or distal (g4) TSS, and position of qPCR primers amplifying different exons of the *HOPX* locus.

(J-M) Analysis of gene expression in control high-density monolayer cells versus replated cells and *HOPX* KD replated cells by qPCR for various exons of the *HOPX* locus (J), genes governing cardiomyocyte hypertrophy (K), cardiac myofibrillar genes (L), and cardiac transcription factors (M).

(N) Morphometric analysis of cell area in control versus *HOPX* KD cells over 64 hr of replating.

(O) Schematic lineage tree showing fate choices governed by *HOPX* during cardiac-directed differentiation and a proposed mechanism whereby hypertrophic signaling is identified as a stimulus required for expression of *HOPX* during *in vitro* differentiation and showing that *HOPX* engages with cardiomyocyte hypertrophic growth through its distal transcriptional start site. For heatmaps, data are presented as Log<sub>10</sub>-transformed relative gene expression normalized to *HPRT*. \* $p < 0.05$ .

(C, E, H, and N) Data are represented as mean  $\pm$  SEM. See also Figure S6 and Table S6.

contrast, inhibition of the distal *HOPX* TSS (g1) resulted in a global reduction of *HOPX* expression (*HOPX* A-E) (Figure 6J). This indicates that *HOPX* has functionally distinct TSSs with the distal TSS functioning as the primary target of regulatory factors driving expression of *HOPX* in the context of hypertrophic stimulation.

To determine the functional requirement of *HOPX* in hypertrophy, we analyzed hypertrophy-related genes (Figure 6K; Table S6). Loss of *HOPX* function from the distal or proximal TSS did not impact expression of any hypertrophic genes tested including *IGF-1* (Figure 6K), the most highly upregulated hypertrophy gene in *HOPX* OE (Figure 5I). We next assessed a panel of cardiac genes associated with maturation. We found that maturation-related myofibrillar genetic isoforms (*MYL2*, *MYH7*, *TNNI3*) were significantly depleted when the distal *HOPX* TSS was inhibited (g1). In contrast, knockdown of the proximal TSS (g4) had small but significant effects on expression of *MYL2* and *MYH7* but a significant increase in expression of the early fetal *MYH6* isoform relative to controls (Figure 6L; Table S6). Expression of selected key cardiac transcription factors was

not impacted by *HOPX* loss of function with the exception of a significant increase in *GATA4* with knockdown of the distal TSS (g1) (Figure 6M; Table S6). These data indicate that, while genetic networks underlying hypertrophy and early cardiomyocyte myofibrillar development are not dependent on *HOPX*, we found it plays a key role driving maturation at least in part through regulating expression of late-stage genetic isoforms of myofibrillogenesis with the distal TSS playing a more dominant role compared to the proximal TSS.

We next assessed the impact of *HOPX* loss of function on morphometric parameters of cardiomyocyte hypertrophy. Cell area was measured at two time points post replating and showed a progressive and significant increase in cell size indicative of cardiomyocyte hypertrophy in control cells and conditions blocking the proximal *HOPX* TSS (g4) (Figure 6N). However, blocking transcription of the distal *HOPX* TSS (g1) attenuated the hypertrophic growth (Figure 6N). Taken together, we have identified *HOPX* as a known key epigenetic regulator of cardiovascular development that is dysregulated during *in-vitro*-directed differentiation from hPSCs. Using genetic models, we show



that *HOPX* is situated downstream of hypertrophic signaling pathways and is essential for downstream expression of cardiac myofibrillar genetic isoforms involved in cardiomyocyte growth and maturation (Figure 6O).

## DISCUSSION

This study provides single-cell transcriptional analysis of human cardiac-directed *in vitro* differentiation. Identification and characterization of *in vitro*-derived cell types are supported by spatiotemporal gene expression of the gastrulating mouse embryo and single-cell analysis of *in vivo* heart development. Cardiac-directed differentiation protocols using small molecules to modulate Wnt signaling have emerged in recent years as a simple, cost-effective, and reliable method to generate high-purity cardiac derivatives from hPSCs. In light of diverse applications of this protocol in cardiovascular discovery and translational research, the current study provides genome-wide analysis of 43,168 cell transcriptomes undergoing stage-specific changes in gene expression during cardiac differentiation as a resource with which to dissect cell subpopulations at the molecular level.

Analysis of subpopulations during early stages of differentiation indicate a surprising contribution of mesendoderm and definitive endoderm coordinately specified with cardiac fates through the progenitor stage of differentiation. In particular, a minority of cells (34%) comprise *MESP1*<sup>+</sup> cardiogenic mesoderm at day 2 that are predicted to ultimately give rise to all cardiac derivatives at day 30. The interaction between endoderm and mesoderm in governing lineage specification *in vivo* is well known, and these data suggest that a critical functional role of induction cues provided by directed differentiation protocols is to establish the necessary population stoichiometry of transiently sustained endoderm required to support mesoderm in the derivation of high-purity cardiac fates *in vitro*.

We evaluated lineage trajectories from single-cell data by implementing a lineage prediction algorithm, *scdiff*, specifically designed for learning regulatory networks controlling differentiation from single-cell time series data. These data revealed insights into the bifurcation of cardiac precursor cells at day 5 of differentiation into *NKX2-5*<sup>+</sup>/*MYL2*<sup>+</sup> ventricular cardiomyocytes and a population of non-contractile cells with transcriptional networks similar to *NKX2-5*<sup>+</sup>/*PITX2*<sup>+</sup> cardiac OFT cells. While previous studies have routinely described a non-contractile *THY1*<sup>+</sup> (*CD90*<sup>+</sup>) fibroblast-like cells for tissue engineering applications (Thavandiran et al., 2013), this population remains poorly studied. We provide single-cell level transcriptome-wide evidence directly linked to *in vivo* cell cardiac types that non-contractile *THY1*<sup>+</sup> cells are similar to cardiac OFT derivatives. Of importance, congenital heart disease (CHD) is among the most common forms of congenital defects and OFT anomalies account for roughly 30% of CHD incidences (Thom et al., 2006). Given the complexity of OFT differentiation and morphogenesis that involves cell types form diverse origins, future work will require analysis of this population as it pertains to the cellular origins of OFT, septum, and other non-contractile cell types of the heart.

It is well established that *in vitro* cardiac differentiation does not generate cardiomyocytes with the transcriptional profile,

cellular diversity, morphometry, or functional maturity of adult *in vivo*-derived cardiomyocytes (Yang et al., 2014). Among a panel of candidate regulatory genes studied, we focused on *HOPX* as a key developmental regulator of cardiac myoblasts early in heart development *in vivo* (Jain et al., 2015) that is rarely expressed in *in vitro*-derived cardiomyocytes. We tested the hypothesis that the dysregulation of *HOPX* was the consequence of deficiencies in directed differentiation accurately mimicking the signaling and mechanical stimuli of the developing heart. To address this, we aimed to understand the basis for activating *HOPX* and its downstream gene networks *in vitro* by identifying the upstream cues required for its expression. Utilizing gain- and loss-of-function genetic models, we provide a comprehensive profiling of the complex transcriptional landscape of *HOPX* as a central regulator of the cardiomyocyte response to hypertrophy. Our data show that the distal TSS is the primary hypertrophy responsive element and regulation of *HOPX* through this TSS functionally governs gene networks and cellular morphometric growth associated with cardiomyocyte hypertrophy and maturation.

Taken together, this study provides insights into the complexity of cell populations represented in stage-specific transitions from pluripotency and establish a unique reference point for dissecting gene networks involved in human cardiac development and disease. Promoting adult-like phenotypes from *in vitro*-differentiated cell types is essential for the realization of the translational applications of hPSCs in disease modeling and therapy. This study provides evidence that *HOPX* expression is a key transcriptional regulator near absent during high-density cardiac-directed differentiation *in vitro*, requiring hypertrophic stimulation to accurately direct *HOPX* and its downstream networks underlying the transcriptional and functional maturity of hPSC-derived cardiomyocytes.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Generation and Maintenance of Human ES-/iPSC Lines
- METHOD DETAILS
  - Cell Culture
  - Quantitative real-time PCR
  - Immunofluorescence and Morphometric Analysis
  - Flow Cytometry
  - Single Cell Isolation
  - Single Cell RNA-Seq
  - Bioinformatics Processing
  - Bulk RNA-Seq
  - Protein Extraction and Western Blot Analysis
  - Genomics Datasets
  - Gene Ontology Visualization
  - Spearman Correlation Analysis
  - iTranscriptome Sample Preparation and Data Analysis



- Constructing Regulatory Differentiation Networks
- scdiff Parameters Used in This Study
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND SOFTWARE AVAILABILITY

## SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and six tables and can be found with this article online at <https://doi.org/10.1016/j.stem.2018.09.009>.

## ACKNOWLEDGMENTS

Sequencing was performed by the Institute for Molecular Bioscience Sequencing Facility at the University of Queensland. Assistance with the Figure 1A schematic was provided by Suzy Hur. The WTC CRISPRi GCaMP hiPSCs and pQM plasmid backbone were kindly provided by the Conklin lab (UCSF, Gladstone Institute). We thank Prof. Richard Harvey (Victor Change Cardiac Research Institute) for assistance in reviewing the draft manuscript. Microscopy was performed at the Australian Cancer Research Foundation (ACRF)/Institute for Molecular Bioscience Cancer Biology Imaging Facility. This work was supported by the Australian Research Council (SR1101002) (N.J.P.), the ARC Discovery Early Career Award (DE160100755) (E.S.W.), and National Health and Medical Research Council grants 1107599 and 1083405 (J.E.P.). Z.B.-J. and J.D. were supported in part by grant 1R01GM122096 from the NIH. This work was also supported by a Strategic Priority Research Program of the Chinese Academy of Sciences (XDA01010201 to N.J., XDA01010303 to J.-D.J.H.), National Key Basic Research and Development Program of China (2014CB964804, 2015CB964500, and 2015CB964803), and National Natural Science Foundation of China (91219303, 31430058, 31401261, 91329302, 31210103916, and 91519330). P.P.L.T. is a Senior Principal Research Fellow of the National Health and Medical Research Council of Australia (1110751).

## AUTHOR CONTRIBUTIONS

C.E.F. generated cells for single-cell RNA-seq, analyzed single cell data, performed genome editing, carried out stem cell work and *HOPX* LOF experiments, and wrote the manuscript. Q.N. led computational analysis and wrote the manuscript. S.W.L. performed single-cell isolation, barcoding, and sequencing and performed computational analysis and edited the manuscript. A.H. performed computational analysis and edited the manuscript. H.S.C. generated cells for single-cell RNA-seq. J.M. generated the *HOPX*-inducible overexpression cell line and carried out *HOPX* OE assays. S.L. assisted in generating the *HOPX*-inducible overexpression cell line. S.S. conceived and generated iTranscriptome data. J.-D.J.H. conceived and generated iTranscriptome data. P.O. assisted with the preparation of iTranscriptome data. G.P. conceived and generated iTranscriptome data. G.J.B. assisted with sequencing. A.S. performed computational analysis of single-cell data. A.N.C. assisted with sequencing. T.J.B. assisted with sequencing. N.J. conceived and generated iTranscriptome data for mouse gastrulation *in vivo*. C.E.M. edited the manuscript. E.S.W. adapted *scdiff* for large-scale single-cell data sets and generated *scdiff* data. J.D. conceived of and developed *scdiff*. Z.B.-J. conceived of and developed *scdiff* and wrote the manuscript. H.R.-B. supervised *HOPX* overexpression assays. Y.W. performed computational analysis of single-cell data and edited the manuscript. J.H. edited the manuscript. P.P.L.T. supervised iTranscriptome analysis, consulted single-cell phenotypes, and edited the manuscript. J.E.P. conceived and supervised experiments involving computational genomics analysis of single-cell RNA-seq data, wrote the manuscript, and generated funding for the work. N.J.P. conceived and supervised experiments involving stem cell differentiation, performed *HOPX* experiments, wrote the manuscript, and generated funding for the work.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: October 28, 2017  
Revised: May 30, 2018  
Accepted: September 13, 2018  
Published: October 4, 2018

## REFERENCES

- Akaike, H. (1998). Information Theory and an Extension of the Maximum Likelihood Principle (Springer).
- Alexa, A., Rahnenführer, J., and Lengauer, T. (2006). Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. *Bioinformatics* 22, 1600–1607.
- Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count data. *Genome Biol.* 11, R106.
- Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq—A Python framework to work with high-throughput sequencing data. *Bioinformatics* 31, 166–169.
- Arrington, C.B., Dowse, B.R., Bleyl, S.B., and Bowles, N.E. (2012). Non-synonymous variants in pre-B cell leukemia homeobox (PBX) genes are associated with congenital heart defects. *Eur. J. Med. Genet.* 55, 235–237.
- Burridge, P.W., Matsa, E., Shukla, P., Lin, Z.C., Churko, J.M., Ebert, A.D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N.M., et al. (2014). Chemically defined generation of human cardiomyocytes. *Nat. Methods* 11, 855–860.
- Chen, F., Kook, H., Milewski, R., Gitler, A.D., Lu, M.M., Li, J., Nazarian, R., Schnepf, R., Jen, K., Biben, C., et al. (2002). Hop is an unusual homeobox gene that modulates cardiac development. *Cell* 110, 713–723.
- Coifman, R.R., Lafon, S., Lee, A.B., Maggioni, M., Nadler, B., Warner, F., and Zucker, S.W. (2005). Geometric diffusions as a tool for harmonic analysis and structure definition of data: Multiscale methods. *Proc. Natl. Acad. Sci. USA* 102, 7432–7437.
- Dal Molin, A., Baruzzo, G., and Di Camillo, B. (2017). Single-cell RNA-sequencing: Assessment of differential expression analysis methods. *Front. Genet.* 8, 62.
- Davies, D.L., and Bouldin, D.W. (1979). A cluster separation measure. *IEEE Trans. Pattern Anal. Mach. Intell.* 1, 224–227.
- DeLaughter, D.M., Bick, A.G., Wakimoto, H., McKean, D., Gorham, J.M., Kathiriy, I.S., Hinson, J.T., Homsy, J., Gray, J., Pu, W., et al. (2016). Single-cell resolution of temporal gene expression during heart development. *Dev. Cell* 39, 480–490.
- Den Hartogh, S.C., Schreurs, C., Monshouwer-Kloots, J.J., Davis, R.P., Elliott, D.A., Mummery, C.L., and Passier, R. (2015). Dual reporter MESP1 mCherry/w-NKX2-5 eGFP/w hESCs enable studying early human cardiac differentiation. *Stem Cells* 33, 56–67.
- Ding, J., Aronow, B.J., Kaminski, N., Kitzmiller, J., Whitsett, J.A., and Bar-Joseph, Z. (2018). Reconstructing differentiation networks and their regulation from time series single-cell expression data. *Genome Res.* 28, 383–395.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21.
- Dubois, N.C., Craft, A.M., Sharma, P., Elliott, D.A., Stanley, E.G., Elefant, A.G., Gramolini, A., and Keller, G. (2011). SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. *Nat. Biotechnol.* 29, 1011–1018.
- Ernst, J., Vainas, O., Harbison, C.T., Simon, I., and Bar-Joseph, Z. (2007). Reconstructing dynamic regulatory maps. *Mol. Syst. Biol.* 3, 74.
- Jain, R., Li, D., Gupta, M., Manderfield, L.J., Ifkovits, J.L., Wang, Q., Liu, F., Liu, Y., Poleshko, A., Padmanabhan, A., et al. (2015). HEART DEVELOPMENT. Integration of Bmp and Wnt signaling by Hopx specifies commitment of cardiomyoblasts. *Science* 348, aaa6071.
- Kook, H., Lepore, J.J., Gitler, A.D., Lu, M.M., Wing-Man Yung, W., Mackay, J., Zhou, R., Ferrari, V., Gruber, P., and Epstein, J.A. (2003). Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. *J. Clin. Invest.* 112, 863–871.
- Kuppusamy, K.T., Jones, D.C., Sperber, H., Madan, A., Fischer, K.A., Rodriguez, M.L., Pabon, L., Zhu, W.Z., Tulloch, N.L., Yang, X., et al. (2015).

- Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes. *Proc. Natl. Acad. Sci. USA* **112**, E2785–E2794.
- Li, G., Xu, A., Sim, S., Priest, J.R., Tian, X., Khan, T., Quertermous, T., Zhou, B., Tsao, P.S., Quake, S.R., and Wu, S.M. (2016). Transcriptomic profiling maps anatomically patterned subpopulations among single embryonic cardiac cells. *Dev. Cell* **39**, 491–507.
- Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L.B., Azarin, S.M., Raval, K.K., Zhang, J., Kamp, T.J., and Palecek, S.P. (2012). Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc. Natl. Acad. Sci. USA* **109**, E1848–E1857.
- Lin, P., Troup, M., and Ho, J.W. (2017). CIDR: Ultrafast and accurate clustering through imputation for single-cell RNA-seq data. *Genome Biol.* **18**, 59.
- Lun, A.T., McCarthy, D.J., and Marioni, J.C. (2016). A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. *F1000Res.* **5**, 2122.
- Mandegar, M.A., Huebsch, N., Frolov, E.B., Shin, E., Truong, A., Olvera, M.P., Chan, A.H., Miyaoka, Y., Holmes, K., Spencer, C.I., et al. (2016). CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs. *Cell Stem Cell* **18**, 541–553.
- Mills, R.J., Titmarsh, D.M., Koenig, X., Parker, B.L., Ryall, J.G., Quaife-Ryan, G.A., Voges, H.K., Hodson, M.P., Ferguson, C., Drowley, L., et al. (2017). Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. *Proc. Natl. Acad. Sci. USA* **114**, E8372–E8381.
- Moignard, V., Woodhouse, S., Haghverdi, L., Lilly, A.J., Tanaka, Y., Wilkinson, A.C., Buettner, F., Macaulay, I.C., Jawaid, W., Diamanti, E., et al. (2015). Decoding the regulatory network of early blood development from single-cell gene expression measurements. *Nat. Biotechnol.* **33**, 269–276.
- Moody, J.D., Levy, S., Mathieu, J., Xing, Y., Kim, W., Dong, C., Tempel, W., Robitaille, A.M., Dang, L.T., Ferreccio, A., et al. (2017). First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor. *Proc. Natl. Acad. Sci. USA* **114**, 10125–10130.
- Murry, C.E., and Keller, G. (2008). Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development. *Cell* **132**, 661–680.
- Nguyen, Q.H., Lukowski, S.W., Chiu, H.S., Senabouth, A., Bruxner, T.J.C., Christ, A.N., Palpant, N.J., and Powell, J.E. (2018). Single-cell RNA-seq of human induced pluripotent stem cells reveals cellular heterogeneity and cell state transitions between subpopulations. *Genome Res.* **28**, 1053–1066.
- Nguyen, Q., Lukowski, S., Chiu, H., Friedman, C., Senabouth, A., Bruxner, T., Christ, A., Palpant, N., and Powell, J. (2018). Determining cell fate specification and genetic contribution to cardiac disease risk in hiPSC-derived cardiomyocytes at single cell resolution. *BioRxiv*. <https://doi.org/10.1101/gr.223925.117>.
- Palpant, N.J., Pabon, L., Rabinowitz, J.S., Hadland, B.K., Stoick-Cooper, C.L., Paige, S.L., Bernstein, I.D., Moon, R.T., and Murry, C.E. (2013). Transmembrane protein 88: A Wnt regulatory protein that specifies cardiomyocyte development. *Development* **140**, 3799–3808.
- Palpant, N.J., Pabon, L., Friedman, C.E., Roberts, M., Hadland, B., Zaunbrecher, R.J., Bernstein, I., Zheng, Y., and Murry, C.E. (2017a). Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells. *Nat. Protoc.* **12**, 15–31.
- Palpant, N.J., Wang, Y., Hadland, B., Zaunbrecher, R.J., Redd, M., Jones, D., Pabon, L., Jain, R., Epstein, J., Ruzzo, W.L., et al. (2017b). Chromatin and transcriptional analysis of mesoderm progenitor cells identifies HOPX as a regulator of primitive hematopoiesis. *Cell Rep.* **20**, 1597–1608.
- Peng, G., Suo, S., Chen, J., Chen, W., Liu, C., Yu, F., Wang, R., Chen, S., Sun, N., Cui, G., et al. (2016). Spatial transcriptome for the molecular annotation of lineage fates and cell identity in mid-gastrula mouse embryo. *Dev. Cell* **36**, 681–697.
- Quaife-Ryan, G.A., Sim, C.B., Ziemann, M., Kaspi, A., Rafehi, H., Ramialison, M., El-Osta, A., Hudson, J.E., and Porrello, E.R. (2017). Multicellular transcriptional analysis of mammalian heart regeneration. *Circulation* **136**, 1123–1139.
- Rousseeuw, P.J. (1987). Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. *J. Comput. Appl. Math.* **20**, 53–65.
- Schulz, M.H., Devanny, W.E., Gitter, A., Zhong, S., Ernst, J., and Bar-Joseph, Z. (2012). DREM 2.0: Improved reconstruction of dynamic regulatory networks from time-series expression data. *BMC Syst. Biol.* **6**, 104.
- Senabouth, A., Lukowski, S., Alquicira, J., Andersen, S., Mei, X., Nguyen, Q., and Powell, J. (2017). *ascend*: R package for analysis of single cell RNA-seq data. *bioRxiv*. <https://doi.org/10.1101/207704>.
- Shin, C.H., Liu, Z.P., Passier, R., Zhang, C.L., Wang, D.Z., Harris, T.M., Yamagishi, H., Richardson, J.A., Childs, G., and Olson, E.N. (2002). Modulation of cardiac growth and development by HOP, an unusual homeo-domain protein. *Cell* **110**, 725–735.
- Thavandiran, N., Dubois, N., Mikryukov, A., Massé, S., Beca, B., Simmons, C.A., Deshpande, V.S., McGarry, J.P., Chen, C.S., Nanthakumar, K., et al. (2013). Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. *Proc. Natl. Acad. Sci. USA* **110**, E4698–E4707.
- Thom, T., Haase, N., Rosamond, W., Howard, V.J., Rumsfeld, J., Manolio, T., Zheng, Z.J., Flegal, K., O'Donnell, C., Kittner, S., et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2006). Heart disease and stroke statistics—2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* **113**, e85–e151.
- Tohyama, S., Hattori, F., Sano, M., Hishiki, T., Nagahata, Y., Matsuura, T., Hashimoto, H., Suzuki, T., Yamashita, H., Satoh, Y., et al. (2013). Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. *Cell Stem Cell* **12**, 127–137.
- Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: Discovering splice junctions with RNA-seq. *Bioinformatics* **25**, 1105–1111.
- Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J., Livak, K.J., Mikkelsen, T.S., and Rinn, J.L. (2014). The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat. Biotechnol.* **32**, 381–386.
- Ueno, S., Weidinger, G., Osugi, T., Kohn, A.D., Golob, J.L., Pabon, L., Reinecke, H., Moon, R.T., and Murry, C.E. (2007). Biphasic role for Wnt/β-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **104**, 9685–9690.
- Uesugi, M., Ojima, A., Taniguchi, T., Miyamoto, N., and Sawada, K. (2014). Low-density plating is sufficient to induce cardiac hypertrophy and electrical remodeling in highly purified human iPSC cell-derived cardiomyocytes. *J. Pharmacol. Toxicol. Methods* **69**, 177–188.
- van den Berg, C.W., Okawa, S., Chuva de Sousa Lopes, S.M., van Iperen, L., Passier, R., Braam, S.R., Tertoolen, L.G., del Sol, A., Davis, R.P., and Mummery, C.L. (2015). Transcriptome of human foetal heart compared with cardiomyocytes from pluripotent stem cells. *Development* **142**, 3231–3238.
- Wei, T., and Simko, V. (2016). *corrplot*: Visualization of a Correlation Matrix. Available from <https://github.com/taiyun/corrplot>
- Wells, C.A., Mosbergen, R., Korn, O., Choi, J., Seidenman, N., Matigian, N.A., Vitale, A.M., and Shepherd, J. (2013). Stemformatics: Visualisation and sharing of stem cell gene expression. *Stem Cell Res. (Amst.)* **10**, 387–395.
- Yang, X., Pabon, L., and Murry, C.E. (2014). Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes. *Circ. Res.* **114**, 511–523.
- Zheng, G.X., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B., Wheeler, T.D., McDermott, G.P., Zhu, J., et al. (2017). Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* **8**, 14049.

## STAR★METHODS

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Mouse monoclonal to $\alpha$ -Actinin (clone EA-53)	Sigma	Cat.#A7811; RRID: AB_476766
Mouse monoclonal to cardiac troponin T (clone 13-11)	ThermoFisher	Cat.#MA5-12960; RRID: AB_11000742
Rabbit polyclonal to Titin C terminus	MyoMedix	Cat.#TTN-9; RRID: AB_2734750
Rabbit polyclonal to $\alpha$ -Tubulin	Cell Signaling Technology	Cat.#2144; RRID: AB_2210548
Rabbit polyclonal to GFP	ThermoFisher	Cat.#A11122; RRID: AB_221569
Rabbit polyclonal Living Colors to DsRed	Clontech Laboratories	Cat.#632496; RRID: AB_10013483
Donkey anti-goat IgG (H+L), AlexaFluor594 conjugated	ThermoFisher	Cat.#A11058; RRID: AB_2534105
Goat anti-mouse IgG (H+L), AlexaFluor594 conjugated	ThermoFisher	Cat.#R37121; RRID: AB_2556549
Goat anti-mouse IgG (H+L), AlexaFluor488 conjugated	ThermoFisher	Cat.#A11001; RRID: AB_2534069
Goat anti-rabbit IgG (H+L), AlexaFluor647 conjugated	ThermoFisher	Cat.#A21244; RRID: AB_2535812
Phalloidin, AlexaFluor568 conjugated	ThermoFisher	Cat.#A12380
Mouse monoclonal to APJ (apelin receptor) (clone 72133), APC conjugated	R&D	Cat.# FAB856A; RRID: AB_2044604
Goat anti-rabbit IgG (H+L), HRP conjugated	BioRad	Cat.#1706515; RRID: AB_11125142
Goat anti-mouse IgG (H+L), HRP conjugated	BioRad	Cat.#1706516; RRID: AB_11125547
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
Vitronectin XF	STEMCELL Technologies	Cat.#07180
mTeSR	STEMCELL Technologies	Cat.#05850
RPMI	ThermoFisher	Cat.#11875119
CHIR99021 (CHIR)	STEMCELL Technologies	Cat.#72054
Bovine Serum Albumin, (BSA)	Sigma	Cat.#A9418
L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (ascorbic acid)	Sigma	Cat.#A8960
XAV939	STEMCELL Technologies	Cat.#72674
B-27 Supplement (50X), serum free	ThermoFisher	Cat.#17504001
Endothelin 1 (ET-1)	Sigma	Cat.#E7764
GeneJuice Transfection Reagent	Merck	Cat.#70967
Blasticidine S hydrochloride (blasticidine)	Sigma	Cat.#15205
Doxycycline hyclate (dox)	Sigma	Cat.#D9891
ROCK inhibitor Y-27632 (ROCKi)	STEMCELL Technologies	Cat.#72308
SuperScript III First-Strand Synthesis System	ThermoFisher	Cat.#18080051
SYBR Green PCR Master Mix	ThermoFisher	Cat.#4312704
Saponin from quillaja bark	Sigma	Cat.#S7900
Paraformaldehyde, (PFA)	Sigma	Cat.#158127
Normal goat serum, (NGS)	Sigma	Cat.#G9023
HyClone Characterized Fetal Bovine Serum (FBS)	GE Healthcare Life Sciences	Cat.#SH30084.03
DMEM/F-12	Sigma	Cat.#11320033
<b>Critical Commercial Assays</b>		
Amata Human Stem Cell Kit #2	Lonza	Cat.#VVPH-5022
Cardiac Hypertrophy H384 qPCR panels	BioRad	Cat.#10025144
Chromium Single Cell 3' Library, Gel Bead and Multiplex Kit	10X Genomics	Cat.#PN-120233
<b>Deposited Data</b>		
scRNA-seq data	This paper	E-MTAB-6268

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Experimental Models: Cell Lines		
Human ESC: RUES2 HOPX KO	(Palpant et al., 2017b)	CVCL_VM28
Human ESC: RUES2 HOPX-tdTomato	(Palpant et al., 2017b)	CVCL_VM29
Human iPSC: WTC CRISPRi GCaMP	Gift from Dr. Bruce Conklin, UCSF, Gladstone Institute, US (Mandegar et al., 2016)	CVCL_VM38
Human iPSC: WTC11 CRISPRi HOPX g4	This paper	AC CVCL_VQ28
Human iPSC: WTC11 CRISPRi HOPX g1	This paper	AC CVCL_VQ27
Human iPSC: WTC11 HOPX-NLS-eGFP	This paper	CVCL_VM46
Human iPSC: WTC11 NLS-eGFP	This paper	CVCL_VM47
Oligonucleotides		
See “WTC CRISPRi HOPX g4 and g1 hiPSCs” and “Quantitative real-time PCR” for qPCR primer sequences and CRISPRi gRNA oligos	This paper	“WTC CRISPRi HOPX g4 and g1 hiPSCs” and “Quantitative real-time PCR”
Software and Algorithms		
STAR software	(Dobin et al., 2013)	N/A
ascend	(Senabouth et al., 2017)	<a href="https://doi.org/10.1101/207704">https://doi.org/10.1101/207704</a>
scraper	(Lun et al., 2016)	<a href="https://bioconductor.org/packages/release/bioc/html/scraper.html">https://bioconductor.org/packages/release/bioc/html/scraper.html</a>
CORE	(Nguyen et al., 2018, 2018)	doi: <a href="https://doi.org/10.1101/119255">https://doi.org/10.1101/119255</a>
Tophat	(Trapnell et al., 2009)	N/A
Htseq-count	(Anders et al., 2015)	N/A
scdiff	(Ding et al., 2018)	<a href="https://github.com/phoenixding/scdiff">https://github.com/phoenixding/scdiff</a>
QuantStudio Software V1.3	Applied Biosystems	N/A
ImageJ	NIH	<a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a>
FlowJo	Tree Star	<a href="https://www.flowjo.com">https://www.flowjo.com</a>
GraphPad Prism 6	GraphPad Software	<a href="http://www.graphpad.com/scientificsoftware/prism/">http://www.graphpad.com/scientificsoftware/prism/</a>
Other		
RNeasy Mini Kit	QIAGEN	Cat.#74106

**CONTACT FOR REAGENT AND RESOURCE SHARING**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Nathan Palpant ([n.palpant@uq.edu.au](mailto:n.palpant@uq.edu.au)).

**EXPERIMENTAL MODEL AND SUBJECT DETAILS****Generation and Maintenance of Human ESC/iPSC Lines**

All human pluripotent stem cell studies were carried out in accordance with consent from the University of Queensland's Institutional Human Research Ethics approval (HREC#: 2015001434). The RUES2-td-Tomato reporter (karyotype: 46, XX; RRID CVCL\_VM29) and RUES2 HOPX KO (karyotype: 46, XX; RRID CVCL\_VM28) human ES cell lines were generated as previously described (Palpant et al., 2017b). WTC CRISPRi GCaMP hiPSCs (Karyotype: 46, XY; RRID CVCL\_VM38), generously provided by M. Mandegar and B. Conklin (UCSF, Gladstone Institute), was generated using a previously described protocol (Mandegar et al., 2016). WTC CRISPRi HOPX g4 (XY; RRID CVCL\_VQ28), WTC CRISPRi HOPX g1 (XY; RRID CVCL\_VQ27), WTC HOPX-NLS-eGFP (XY; RRID CVCL\_VM46), and WTC NLS-eGFP (XY; RRID CVCL\_VM47) hiPSCs were generated in this study (see below). All cells were maintained as previously described (Palpant et al., 2017a). Briefly, cells were maintained in mTeSR media with supplement (Stem Cell Technologies, Cat.#05850) at 37°C with 5% CO<sub>2</sub>. All hESCs, WTC HOPX-NLS-eGFP, and WTC NLS-eGFP lines were maintained on matrigel growth factor reduced basement membrane matrix (Corning, Cat.#356231), while WTC CRISPRi, WTC CRISPRi HOPX g4, and WTC CRISPRi HOPX g1 hiPSC lines were maintained on Vitronectin XF (Stem Cell Technologies, Cat.#07180) coated plates. Despite no overt abnormalities, WTC CRISPRi cells and their derivatives are non-wild-type and comprise the sole cell type analyzed by scRNA-seq. Further verification of these findings using different cell lines is suggested.



### WTC CRISPRi HOPX g4 and g1 hiPSCs

HOPX-targeted guide RNAs (gRNA) were designed to target sequences near the human HOPX distal and proximal transcription start sites, were cloned into the pQM-u6g-CNKB doxycycline-inducible construct and transfected into WTC CRISPRi GCaMP hiPSCs using GeneJuice Transfection Reagent (Merck, Cat.#70967). Stable clones were selected using successive rounds of re-plating with blasticidine at 10 µg/ml (Sigma, Cat.#15205). Populations were tested for knockdown efficiency by qPCR following doxycycline addition at 1 µg/ml (Sigma, Cat.#D9891) continuously from day 0 of cardiac-directed differentiation.

Guide RNAs targeting the HOPX transcription start site.

gRNA Name	Oligo Sequences
	5' – Forward Primer – 3'
	5' – Reverse Primer – 3'
gRNA4	TTGGCCTTCCTTAGAGCCGGAGGT
	AAACACCTCCGGCTCTAAGGAAGG
gRNA1	TTGGCTCATTTCAAAGCGTAGATC
	AAACGATCTACGCTTTGAAATGAG

### WTC HOPX-NLS-eGFP and WTC NLS-eGFP hiPSCs

We cloned the human HOPX ORF fused to a nuclear localization sequence (CCAAAGAAGAAGCGGAAGGTC) and GFP into the AAVS1 targeting plasmid (pZDonor, Sigma).  $1 \times 10^6$  WT WTC hiPSCs were transfected with 0.5 µg AAVS1-TALEN, 0.5 µg AAVS1-TALEN and 4 µg of HOPX-NLS-eGFP or 4 µg of NLS-eGFP to generate the HOPX line and the negative control line, respectively, using Amaxa Human stem cell Kit #2 (Lonza, Cat.#VVPH-5022). The cells were then plated with 5mM ROCK inhibitor onto Matrigel-coated plates in mTeSR. Two days following the nucleofection, the cells were selected for puromycin resistance using puromycin at 0.5 µg/ml for 48 hours.

## METHOD DETAILS

### Cell Culture

All human pluripotent stem cell studies were carried out in accordance with consent from the University of Queensland's Institutional Human Research Ethics approval (HREC#: 2015001434). hESCs and hiPSCs were maintained in mTeSR media (Stem Cell Technologies, Cat.#05850). Unless otherwise specified, cardiomyocyte directed differentiation using a monolayer platform was performed with a modified protocol based on previous reports (Burridge et al., 2014; Lian et al., 2012). On day –1 of differentiation, hPSCs were dissociated using 0.5% EDTA, plated into vitronectin or matrigel coated plates at a density of  $1.8 \times 10^5$  cells/cm<sup>2</sup>, and cultured overnight in mTeSR media. Differentiation was induced on day 0 by first washing with PBS, then changing the culture media to RPMI (ThermoFisher, Cat.#11875119) containing 3 µM CHIR99021 (Stem Cell Technologies, Cat.#72054), 500 µg/mL BSA (Sigma Aldrich, Cat.#A9418), and 213 µg/mL ascorbic acid (Sigma Aldrich, Cat.#A8960). After 3 days of culture, the media was replaced with RPMI containing 500 µg/mL BSA, 213 µg/mL ascorbic acid, and 1 µM Xav-939 (Stem Cell Technologies, Cat.#72674). On day 5, the media was exchanged for RPMI containing 500 µg/mL BSA, and 213 µg/mL ascorbic acid without supplemental cytokines. From day 7 onward, the cultures were fed every 2 days with RPMI plus 1x B27 supplement plus insulin (Life Technologies Australia, Cat.#17504001). For endothelin-1 assays, cells were treated with 300nM ET-1 (Sigma-Aldrich, Cat.#E7764) from day 9-15 of directed differentiation. For HOPX overexpression studies (Figure 5), the following protocol was utilized: A monolayer-based directed differentiation protocol was followed to generate hiPSC-CMs, as described previously (Palpant et al., 2017a). On day 15 hiPSC-CMs were enriched by lactate selection (Tohyama et al., 2013).

### Quantitative real-time PCR

For quantitative real-time PCR, total RNA was isolated using the RNeasy Mini kit (QIAGEN, Cat.#74106). First-strand cDNA synthesis was generated using the Superscript III First Strand Synthesis System (ThermoFisher, Cat.#18080051). Quantitative real-time PCR was performed using SYBR Green PCR Master Mix (ThermoFisher, Cat.#4312704) on a ViiA 7 Real-Time PCR System (Applied Biosystems). The copy number for each transcript is expressed relative to that of housekeeping gene *HPRT1*. Quantification of cardiac hypertrophy gene expression was performed using Cardiac Hypertrophy H384 qPCR panels (BioRad, Cat.#10025144) with SYBR Green PCR Master Mix. Samples were run in biological triplicate. The copy number for each transcript is expressed relative to that of housekeeping gene *HPRT1*. FC was calculated on a gene by gene basis as gene expression divided by control gene expression.

#### qRT PCR primers

Gene Name	Forward Primer	Reverse Primer
<i>HPRT</i>	TGACACTGGCAAAACAATGCA	GGTCCTTTTCACCAGCAAGCT
<i>GATA4</i>	GACCTGGGACTTGGAGGATA	ACAGGAGAGATGCAGTGTGC
<i>NKX2-5</i>	CAAGTGTGCGTCTGCCTTT	CAGCCTTCTTTTCGGCTCTA
<i>MYL4</i>	TCAAAGAGGCCTTTTCATTG	CGTCTCAAAGTCCAGCATCT
<i>MYL2</i>	TTGGGCGAGTGAACTGAAAA	CCGAACGTAATCAGCCTTCAG
<i>MYH6</i>	CAAGTTGGAAGACGAGTGCT	ATGGGCCTCTTGATAGAGCTT
<i>MYH7</i>	GGGCAACAGGAAAGTTGGC	ACGGTGGTCTCTCCTTGGG
<i>TNNI1</i>	CCCAGCTCCACGAGGACTGAACA	TTTGCGGGAGGCAGTGATCTTGG
<i>TNNI3</i>	GGAACCTCGCCCTGCACCAG	GCGCGGTAGTTGGAGGAGCG
<i>ATP2A2</i>	TTTCCTACAGTGTAAGAGGACAACC	TTCCAGGTAGTTGCGGGCCACAAA
<i>HOPX A</i>	GCCCAGCTATTTAAGCAGGC	GGGTGCTTGTGCACCTTGTT
<i>HOPX B</i>	ATGCTCATTTTCTGGGCTGT	GGGTGCTTGTGCACCTTGTT
<i>HOPX C</i>	CCACCCTCGCGATCTGTCAA	GGGTGCTTGTGCACCTTGTT
<i>HOPX D</i>	CAAGGTCGACAAGCACCCGGATTC	GGGTACTTTCTGGGTGCCA
<i>HOPX E</i>	CAAGGTCGACAAGCACCCGGATTC	CATCTCCTTAGTCTGTGACGGA
<i>SRF</i>	CGAGATGGAGATCGGTATGGT	GGGTCTTCTTACCCGGCTTG

#### Immunofluorescence and Morphometric Analysis

Cells were fixed with 4% paraformaldehyde, permeabilized in PBS containing 0.025% Triton-X, and blocked in PBS containing 1.5% normal goat serum. Cells were stained with alpha-actinin (Clone EA-53; Sigma-Aldrich Cat# A7811, RRID:AB\_476766) at 1:800 and dsRed (Clontech Laboratories, Cat# 632496, RRID:AB\_10013483) followed by secondary staining with AlexaFluor-594 Donkey Anti-Goat (ThermoFisher, Cat# A-11058, RRID:AB\_2534105 lot #1180089, 1:200) or AlexaFluor-594 Goat Anti-Mouse (ThermoFisher, Cat# R37121, RRID:AB\_2556549 lot # 1219862, 1:200). Nuclei were counterstained with DAPI. For *HOPX* overexpression studies (Figure 5), cells were fixed in 4% (vol/vol) paraformaldehyde, blocked for an hour with 5% (vol/vol) normal goat serum (NGS) (Sigma, Cat.#G9023), and incubated overnight with primary antibody in 1% NGS, followed by secondary antibody staining in NGS. Measurements of CM area were performed using ImageJ software. Analysis was done on a Leica TCS-SPE Confocal microscope using a 40x or 63x objective and Leica Software. Primary antibodies used were:  $\alpha$ Actinin 1:250 (Clone EA-53; Sigma-Aldrich Cat# A7811, RRID:AB\_476766), Titin 1:300 TTN-9 (cTerm) anti-rabbit (MyoMedix, Cat# TTN-9, RRID:AB\_2734750), GFP 1:300 anti-rabbit (ThermoFisher, Cat# A-11122, RRID:AB\_221569). Secondary antibodies and other reagents used were: DAPI at a concentration of 0.02  $\mu$ g/mL, phalloidin alexa fluor 568 1:250 (ThermoFisher, Cat#A12380), goat anti-mouse alexa fluor 488 (ThermoFisher, Cat# A-11001, RRID:AB\_2534069) or goat anti-rabbit alexa fluor 647-conjugated (ThermoFisher, Cat# A-21244, RRID:AB\_2535812) secondary antibodies at 1:500.

#### Flow Cytometry

Cells were fixed with 4% paraformaldehyde (Sigma, Cat.#158127) and permeabilized in 0.75% saponin (Sigma, Cat.#S7900). Cells were labeled for flow cytometry using cardiac troponin T (ThermoFisher, Cat# MA5-12960, RRID:AB\_11000742) or APLNR (R&D, Cat# FAB856A, RRID:AB\_2044604) and corresponding isotype control. Cells were analyzed using a BD FACSCANTO II (Becton Dickinson, San Jose, CA) with FACSDiva software (BD Biosciences). Data analysis was performed using FlowJo (Tree Star, Ashland, Oregon).

#### Single Cell Isolation

For each differentiated day 0, 2, 5, 15, and 30 time point, differentiated cells were dissociated with 0.5% EDTA + 0.25% Trypsin (ThermoFisher, Cat.#15400054) and neutralized with fetal bovine serum (GE Healthcare Life Sciences, Cat.#SH30084.03) and DMEM/F12 media (Sigma, Cat.#11320033) (1:1 ratio). For each time point, 2 pooled samples were collected, each pool comprised approximately 12 independent differentiation samples. Cells were centrifuged at 1200 rpm for 4 minutes and resuspended in Dulbecco's PBS (GIBCO; Cat.#14190) with 0.04% bovine serum albumin (Sigma Aldrich, Cat.#B6917) and immediately transported for scRNA-Seq processing. Viable cells were sorted using a Propidium Iodide stain and retained on ice in Dulbecco's PBS + 0.04% bovine serum albumin. A Countess automated counter (Invitrogen) was used to check final cell viability using Trypan Blue exclusion.

#### Single Cell RNA-Seq

A Chromium instrument (10X Genomics, Millennium Sciences) was used to partition sorted, viable cell suspensions ( $8 \times 10^5$ – $1 \times 10^6$  cells/mL) into single cell droplets using the Single Cell 3' Library, Gel Bead and Multiplex Kit (version 1, 10X Genomics, Cat.#PN-120233) as per the manufacturer's protocol. Each time point was run in duplicate, resulting in 10 sample preparations. The samples

were loaded into Single Cell 3' chips (10X Genomics) at a concentration optimized to capture approximately 5,000 cells in individual 1-cell droplets. Single cell libraries were sequenced using an Illumina NextSeq 500 instrument as previously described (Nguyen et al., 2018).

### Bioinformatics Processing

Bioinformatics mapping of reads to original transcripts and cells was by *cellranger* pipeline v1.3.1 by 10X Genomics (<http://www.10xgenomics.com/>). We used *cellranger mkfastq* to prepare demultiplexed raw base call files into library-specific FASTQ files, with the following parameters—`use-bases-mask = "Y26n*,I8n*,n*,Y98n*"—ignore-dual-index`. The FASTQ files were separately mapped to the GRC38p7 human reference genome using the STAR21 (Dobin et al., 2013) as a part of the *cellranger* pipeline. Gene expression counts were done using *cellranger count* based on Gencode v25 annotation and cell identifiers and Unique Molecular Identifiers (UMI) were filtered and corrected with default setting. Raw *cellranger count* outputs for two biological replicates in each time point were aggregated and normalized by a subsampling procedure using *cellranger aggr* (Zheng et al., 2017). After sample-to-sample normalization, we filtered outlier genes and cells which were outside the range of 3x median absolute deviation (MAD) of the number of cells with the detected genes, ribosomal reads, mitochondrial reads, and total read mapped to cells to remove noise due to sequencing depth or cell conditions. Further, cells with above 50% ribosomal reads, or above 20% mitochondrial reads, and genes detected in fewer than 0.1% total cells were also removed. Post filtering, cell-to-cell normalization was done by *scraper* using pooling sizes of 40, 60, 80 and 100 without using a *quickClustering* option (Lun et al., 2016). Data dimensionality reduction by PCA and *t*-SNE are previously described in Nguyen et al. (Nguyen et al., 2018) and as is implemented in the R *ascend* package (Senabouth et al., 2017). Briefly, PCA using the R *prcomp* function was based on the top 1500 most variable genes. We selected the top 10 principal components (PCs) that explained most variance, as confirmed by *Scree* plot using *fa.parallel* package. For visualization, non-linear dimensionality reduction using *Rtsne* v0.13 package for the top 10 PCs was performed to produce coordinates for cells in 2 dimensional or 3 dimensional tSNE space.

Clustering algorithm was described in Nguyen et al. (2018 and 2018) and is implemented in the *ascend* (Senabouth et al., 2017) as well as the *scGPS* R packages. Briefly, for each aggregated dataset in each time point, we calculated the top 10 PCs as the input for the CORE clustering algorithm. We first built a high-resolution clustering tree structure based on cell-to-cell Euclidean distance and Ward's minimum variance with an agglomerative hierarchical clustering (HAC). The branches in the dendrogram tree were dynamically grouped into clusters by a *cuttreeDynamic* method in the *dynamicTreeCut* v1.63 package. We performed dynamic clustering 40 times for different height cutoffs spanning 99% of the joining height of the initial dendrogram distance tree. The resulting clusters from the 40 runs were compared by using adjusted Rand indexes (ARI) to find a stable clustering point (Nguyen et al., 2018). The optimal clustering point meets two criteria, including robust to changing parameters and less different from a reference with the highest number of clusters. We validated the CORE clustering results using multiple dimensionality reduction and clustering methods, including PCA, tSNE, Multidimensional Scaling (MDS) and Clustering through Imputation and Dimensionality Reduction (CIDR) (Lin et al., 2017).

The processed data post filtering, normalization, and clustering was used as the input for differential expression analysis. We performed DESeq (Anders and Huber, 2010) analysis to find differentially expressed genes between cells in one subpopulation compared to all remaining cells in other subpopulations at a given time-point. We observed that when comparing subpopulations with different number of cells, DESeq was faster and produced more stable performance than DESeq2, consistent to the report by Dal Molin et al. (Dal Molin et al., 2017). Briefly, one pseudocount was added to *scraper* cell-to-cell normalized counts, which were then rounded to integer values before estimating dispersion (with the `fitType` option set to `local`) and running negative binomial test function in DESeq. After significant testing, we performed fold change adjustments to subtract mean expression by one, which allowed more accurate estimation of fold changes for lowly expressed genes. Bonferroni correction as applied to account for multiple testing error.

Furthermore, for reproducibility and broader usability of the valuable data resource, we have submitted all data to Array Express and created a web database resource with interactive data mining tools for users to explore the entire dataset without requirement for programming.

### Bulk RNA-Seq

hiPSC-CMs were harvested for RNA preparation and genome wide RNA-seq (> 20 million reads). RNA-seq samples were aligned to hg19 using Tophat, version 2.0.13 (Trapnell et al., 2009). Gene-level read counts were quantified using *htseq-count* (Anders et al., 2015) using Ensembl GRCh37 gene annotations. Genes with total expression above 1 normalized read count across RNA-seq samples in each binary comparison (e.g., HOPX versus control) were kept for differential analysis using DESeq (Anders and Huber, 2010). *Princomp* function from R was used for Principal Component Analysis. *TopGO* R package (Alexa et al., 2006) was used for Gene Ontology enrichment analysis.

### Protein Extraction and Western Blot Analysis

Cells were lysed directly on the plate with a lysis buffer containing 20mM Tris-HCl pH 7.5, 150mM NaCl, 15% Glycerol, 1% Triton X-100, 1M  $\beta$ -Glycerolphosphate, 0.5M NaF, 0.1M Sodium Pyrophosphate, Orthovanadate, PMSF and 2% SDS (Moody et al., 2017). 25U of Benzonase Nuclease (EMD Chemicals, Gibbstown, NJ) was added to the lysis buffer right before use. Proteins were quantified by Bradford assay (Bio-rad), using BSA (Bovine Serum Albumin) as Standard using the EnWallac Vision. The protein samples were combined with the 4x Laemmli sample buffer, heated (95°C, 5min), and run on SDS-PAGE (protean TGX pre-casted

4%–20% gradient gel, Bio-rad) and transferred to the Nitro-Cellulose membrane (Bio-Rad) by semi-dry transfer (Bio-Rad). Membranes were blocked for 1 hr with 5% milk and incubated in the primary antibodies overnight at 4°C. The membranes were then incubated with secondary antibodies (1:10000, goat anti-rabbit [Cat.#1706515; RRID: AB\_11125142] or goat anti-mouse [Cat.# 1706516; RRID: AB\_11125547] IgG HRP conjugate (Bio-Rad) for 1 hr and the detection was performed using the immobilon-luminol reagent assay (EMD Millipore). Primary antibodies are as follows: Alpha tubulin antibody at 1:2000 (Cell Signaling Technology Cat# 2144, RRID:AB\_2210548) and anti-GFP anti-rabbit at 1:1000 (Invitrogen, Cat# A-11122, RRID AB\_221569).

### Genomics Datasets

Previously published ChIP-seq and gene expression datasets were analyzed for this study. Analysis of cardiac differentiation chromatin dynamics and gene expression by RNA-seq were published previously (Kuppusamy et al., 2015; Palpant et al., 2017b) with data accessed from GEO GSE97080. *HOPX* gene expression analysis were derived from Stemformatics (Wells et al., 2013) using the following datasets: a dual reporter MESP1-mCherry/NKX2-5 GFP reporter hESC line at day 0 and day 3 of directed differentiation sorted for MESP1 positive versus negative cells (Stemformatics ID: Hartogh\_2015\_25187301) (Den Hartogh et al., 2015) and human fetal heart samples isolated at each of three trimesters comparing ventricle and atrial expression (Stemformatics ID: van den berg\_2015\_26209647) (van den Berg et al., 2015). Human fetal heart gene expression data were downloaded from ENCODE (experiment #: ENCSR047LLJ, ENCSR863BUL, ENCSR769LNJ, ENCSR433XCV, and ENCSR675YAS). *HOPX* expression in engineered tissue, adult heart tissue, and hPSC-CMs were acquired from previous work by Mills et al. (Mills et al., 2017).

### Gene Ontology Visualization

Gene ontology analysis was performed using DAVID with significance threshold set at FDR < 0.05. The p values from gene ontology analysis were visualized using the R package corplot (Wei and Simko, 2016), where the radius of the circle is proportional to the negative natural log of the input p value.

### Spearman Correlation Analysis

We obtained FACS sorted bulk cardiac subtypes (Quaife-Ryan et al., 2017) and single-cell RNA-seq data generated from developing mouse heart (Li et al., 2016). The normalized expression data from these two sources was merged with our scRNA-seq expression data. Mouse Ensembl IDs were converted to human ortholog gene IDs and a new expression matrix was generated using only the 13,490 genes common to all three datasets. Spearman's rank correlation was used to compare the expression levels of genes between samples, and the significance of the differences between pairs of correlation coefficients were calculated using a Fisher Z-transformation.

### iTranscriptome Sample Preparation and Data Analysis

Samples were generated according to the methodology published in (Peng et al., 2016). E6.5, E7.0 and E7.5 embryos (n = 6, 6, and 3 respectively) were cryo-sectioned along the proximal-distal axis. Populations of approximately 20 cells were collected from different regions of the cross-section by laser microdissection and processed for RNA sequencing. Two sets of embryos for each embryonic age were dissected: the first set from the epiblast - E6.5: anterior and posterior; E7.0: anterior, left, right and posterior; E7.5: anterior, left anterior and posterior, right anterior and posterior, posterior. The second set from the three germ layers - E6.5: posterior epiblast and endoderm: anterior and posterior; E7.0: posterior epiblast, mesoderm: anterior and posterior, and endoderm: anterior and posterior; E7.5: posterior epiblast, mesoderm: anterior and posterior, and endoderm: anterior and posterior. Differentially expressed genes (DEGs) were screened first by unsupervised hierarchical clustering method to group samples in the respective regions. Genes with an expression level FPKM > 1 and a variance in transcript level across all samples greater than 0.05 were selected. To identify inter-region specific DEGs, each of these selected genes was submitted to a t test against the level of expression in the other regions. Genes with a p.value < 0.01 and a fold change > 2.0 or < 0.5 were defined as DEGs. The gene expression pattern (region and level of expression by transcript reads) of the gene of interest was mapped on the corn plots, where each kernel represents the cell population sampled at a defined position in the germ layers, to generate a digital rendition of whole mount *in situ* hybridization.

### Constructing Regulatory Differentiation Networks

#### Scdiff

Detailed computational model and derivation for *scdiff* are provided in (Ding et al., 2018). *scdiff* software is available on GitHub (<https://github.com/phoenixding/scdiff>). The method is initialized using Spectral clustering based on cell-to-cell Spearman correlation, followed by an ensemble strategy to determine the optimal *K* clusters. The model then iteratively connects clusters (representing states in the probabilistic model) between time points using a "Similarity To Ancestor-STA" strategy (with day 0 as the first time-point), based on expression similarity (Spearman correlation). Cell reassignment is based on a Kalman filter probabilistic model. The initial set of states and their connectivity is iteratively updated by learning trajectory and branching models constrained by transcription factor (TF)-gene interactions via a logistic regression classifier to maximize the ability to predict the expression of target gene based on the interaction data.

Details of the implementation of *scdiff* are outlined below.



### Initial Clustering of Single Cells

*scdiff* starts by clustering the cells in each of the time points measured. While the original *scdiff* method used spectral clustering, this method was unable to scale for the large number of cells profiled in this study. We have thus revised *scdiff* for this study by changing the original clustering methods to a more efficient method. Specifically, we used PCA with 10 dimensions followed by K-means for the initial clustering which led to faster runtime while not greatly affecting performance. To determine the initial number of clusters (*k*) for each time point we combine 3 widely used clustering quality assessment scores: the Silhouette Score (Rousseeuw, 1987), Davis-Bouldin index (Davies and Bouldin, 1979) and AIC (Akaike, 1998) (Akaike information criterion). We used a bootstrapping strategy to combine these. We first selected a random subset of 90% of the genes. Next, we calculate the Silhouette score, Davis Bouldin score and AIC scores for different *k* values between 2 and 20 for each time point. We compute a combined score for each of these *k* values based on the subset of genes selected and repeat this process 100 times (each time with a new random gene subset). We select the optimal *k* by summing up the scores for each of the possible *k* values across the 100 repeats.

### Initial Model Construction

Initial clustering is based on the time point associated with each cell. However, several recent studies indicate that cells may be unsynchronized with respect to their state even if they are collected at the same time point (Trapnell et al., 2014). Thus, some of the clusters at a specific time point may represent states that are either earlier or later than other clusters in the same time. To address this we next use a correlation-based method to reassign clusters to time points. Once we determined the set of clusters associated with each level (time point), we connect clusters in each level to the most similar cluster (in terms of correlation) at the level directly above it (its parent cluster). This leads to a directed graph with potentially multiple roots (initial set of clusters for the first time points) which structurally represents the initial differentiation model.

### Predicting TFs Regulating Differentiation Pathways

An important aspect of *scdiff* is the ability to both reconstruct and analyze the differentiation pathways based on the set of TFs that regulate various state transitions. We used bulk TF-gene interaction data from (Ernst et al., 2007; Schulz et al., 2012) for this analysis. Following the initial model construction, we first identify a set of differentially expressed (DE) genes for each cluster (state) in our model. Using this set, we identify TFs that are enriched for DE targets based on the hyper-geometric distribution. Next, we check which of the candidate TFs is expressed in the parent node of the state. TFs that are both significantly enriched and expressed are used in the to define a logistic regression function which modifies the likelihood of assigning cells to the different clusters in the model. Thus, cell assignment is based on both, expression similarity to other cells in the state and the expression of targets of TFs predicted to regulate this state.

### Iterative Assignment of Cells to States

Given initial assignments of cells and TFs to states, we can compute the MLE of the transition and emission noise variance. We next iterate between two steps. The first uses the parameters learned to reassign cells and TFs to states and the second uses the assigned cells and TFs to re-learn model parameters. During the iterative process some states may become empty and if this happens they are removed from the model. The process stops when it converges (no more cells are re-assigned) and the resulting model is returned.

### scdiff Parameters Used in This Study

*scdiff* was run with the following parameters: -k auto -l 1 -s 1 -d 1. For the *scdiff* input expression matrix, we performed, as described above, a thorough quality check to remove outlier genes and cells (outside 3 x median absolute deviation range) based on mitochondrial, ribosomal genes, library sizes, and number of detected cells. This data processing pipeline was implemented in the *ascend* pipeline (Senabouth et al., 2017). The preprocessed expression data matrix was then normalized at two levels (as described above): by batches (using the *cellranger agg* function), and then by cells (using the deconvolution method in the *scr* package). The filtered and normalized matrix was then used for *scdiff*.

## QUANTIFICATION AND STATISTICAL ANALYSIS

Unless otherwise noted, all data are represented as mean  $\pm$  standard error of mean (SEM). Indicated sample sizes (*n*) represent biological replicates including independent cell culture replicates and individual tissue samples. No methods were used to determine whether data met assumptions of the statistical approach or not. Due to the nature of the experiments, randomization was not performed and the investigators were not blinded. Statistical significance was determined in GraphPad Prism 7 software by using Student's *t* test (unpaired, two-tailed) or ordinary one-way ANOVA unless otherwise noted. Results were considered to be significant at  $p < 0.05$  (\*). Statistical parameters are reported in the respective figures and figure legends.

Quantification of data used for statistical analysis in this study are described here in detail. For single cell analysis, cell numbers for each time point and subpopulation are as follows: day 0, *n* = 13,679; day 2, *n* = 5,905 (*n* = 2,245 cells in S1, *n* = 1,994 cells in S2, and *n* = 1,666 cells in S3); day 5, *n* = 9,827 (*n* = 3,850 cells in S1, *n* = 2,577 cells in S2, *n* = 2,474 cells in S3, and *n* = 924 cells in S4); day 15, *n* = 6,303 (*n* = 3,520 cells in S1 and *n* = 2,783 cells in S2); day 30, *n* = 7,039 (*n* = 4,038 cells in S1, *n* = 3,001 cells in S2). For single cell analysis of developing mouse heart (Li et al., 2016) *n* = 949 cells from two biological replicates.

For iTranscriptome analysis: E6.5 (*n* = 6) and E7.5 (*n* = 6) mouse embryos and published data for E7.0 (*n* = 3) mouse embryos. Color scales represent levels of expression as  $\log_{10}$  of fragments per kilobase million (FPKM + 1).

For Spearman rank correlation analysis (Figure 3H). Values are presented median Spearman's value  $\rho$ . Significant differences between pairs of correlation coefficients were calculated using a Fisher Z-transformation. *P*-values for all tests were below the double precision limit of  $2.2\text{e-}308$ .

For all results  $n = 3\text{--}16$  biological replicates from up to 8 independent experiments.

Immunohistochemistry morphometric analysis: For Figures 6B and 6C  $n = 144$  cells 16 hours post replating and 77 cells 64 hours post replating. Statistics performed using t test with Welch's correction,  $p < 0.0001$  (\*\*\*\*) and  $p < 0.0009$  (\*\*\*). For Figure 6N  $n = 57\text{--}144$  biological replicates per condition for g4 cells and  $n = 52\text{--}78$  biological replicates per condition for g1 cells.

#### DATA AND SOFTWARE AVAILABILITY

scRNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI (<https://www.ebi.ac.uk/arrayexpress>) under accession number E-MTAB-6268.